JP5816170B2 - 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 - Google Patents
天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 Download PDFInfo
- Publication number
- JP5816170B2 JP5816170B2 JP2012517780A JP2012517780A JP5816170B2 JP 5816170 B2 JP5816170 B2 JP 5816170B2 JP 2012517780 A JP2012517780 A JP 2012517780A JP 2012517780 A JP2012517780 A JP 2012517780A JP 5816170 B2 JP5816170 B2 JP 5816170B2
- Authority
- JP
- Japan
- Prior art keywords
- protein
- region
- bispecific
- heavy chain
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
- C07K1/08—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
- C07K1/08—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
- C07K1/088—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents containing other elements, e.g. B, Si, As
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/247—IL-4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22068709P | 2009-06-26 | 2009-06-26 | |
| US61/220,687 | 2009-06-26 | ||
| PCT/US2010/040028 WO2010151792A1 (en) | 2009-06-26 | 2010-06-25 | Readily isolated bispecific antibodies with native immunoglobulin format |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015187704A Division JP6247673B2 (ja) | 2009-06-26 | 2015-09-25 | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012531439A JP2012531439A (ja) | 2012-12-10 |
| JP2012531439A5 JP2012531439A5 (enExample) | 2013-08-01 |
| JP5816170B2 true JP5816170B2 (ja) | 2015-11-18 |
Family
ID=42738900
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012517780A Active JP5816170B2 (ja) | 2009-06-26 | 2010-06-25 | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| JP2015187704A Active JP6247673B2 (ja) | 2009-06-26 | 2015-09-25 | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| JP2017221813A Withdrawn JP2018035193A (ja) | 2009-06-26 | 2017-11-17 | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| JP2020173738A Active JP7153048B2 (ja) | 2009-06-26 | 2020-10-15 | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| JP2022157863A Withdrawn JP2022173489A (ja) | 2009-06-26 | 2022-09-30 | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| JP2024216456A Pending JP2025026680A (ja) | 2009-06-26 | 2024-12-11 | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015187704A Active JP6247673B2 (ja) | 2009-06-26 | 2015-09-25 | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| JP2017221813A Withdrawn JP2018035193A (ja) | 2009-06-26 | 2017-11-17 | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| JP2020173738A Active JP7153048B2 (ja) | 2009-06-26 | 2020-10-15 | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| JP2022157863A Withdrawn JP2022173489A (ja) | 2009-06-26 | 2022-09-30 | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| JP2024216456A Pending JP2025026680A (ja) | 2009-06-26 | 2024-12-11 | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
Country Status (24)
| Country | Link |
|---|---|
| US (7) | US8586713B2 (enExample) |
| EP (3) | EP2445936A1 (enExample) |
| JP (6) | JP5816170B2 (enExample) |
| KR (5) | KR20120027055A (enExample) |
| CN (2) | CN103833855A (enExample) |
| AU (2) | AU2010265933B2 (enExample) |
| CA (1) | CA2766220C (enExample) |
| CY (1) | CY1124358T1 (enExample) |
| DK (1) | DK2975051T3 (enExample) |
| ES (1) | ES2865648T3 (enExample) |
| HR (1) | HRP20210637T1 (enExample) |
| HU (1) | HUE054257T2 (enExample) |
| IL (2) | IL217000A0 (enExample) |
| LT (1) | LT2975051T (enExample) |
| MX (5) | MX384993B (enExample) |
| MY (4) | MY199658A (enExample) |
| PL (1) | PL2975051T3 (enExample) |
| PT (1) | PT2975051T (enExample) |
| RU (3) | RU2522002C2 (enExample) |
| SG (1) | SG176868A1 (enExample) |
| SI (1) | SI2975051T1 (enExample) |
| SM (1) | SMT202100250T1 (enExample) |
| TW (1) | TWI507525B (enExample) |
| WO (1) | WO2010151792A1 (enExample) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015227386A (ja) * | 2009-06-26 | 2015-12-17 | リジェネロン・ファーマシューティカルズ・インコーポレ | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| US9975966B2 (en) | 2014-09-26 | 2018-05-22 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing theraputic agent |
| US11485790B2 (en) | 2014-04-07 | 2022-11-01 | Chugai Seiyaku Kabushiki Kaisha | Immunoactivating antigen-binding molecule |
| US11505605B2 (en) | 2014-05-13 | 2022-11-22 | Chugai Seiyaku Kabushiki Kaisha | T cell-redirected antigen-binding molecule for cells having immunosuppression function |
| US11649293B2 (en) | 2015-11-18 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for enhancing humoral immune response |
| US11660340B2 (en) | 2015-11-18 | 2023-05-30 | Chugai Seiyaku Kabushiki Kaisha | Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function |
Families Citing this family (649)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090137416A1 (en) | 2001-01-16 | 2009-05-28 | Regeneron Pharmaceuticals, Inc. | Isolating Cells Expressing Secreted Proteins |
| NZ537277A (en) | 2002-07-18 | 2008-04-30 | Crucell Holland Bv | Recombinant production of mixtures of antibodies |
| USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
| US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
| WO2004106375A1 (en) | 2003-05-30 | 2004-12-09 | Merus Biopharmaceuticals B.V. I.O. | Fab library for the preparation of anti vegf and anti rabies virus fabs |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| JP5838021B2 (ja) | 2005-04-15 | 2015-12-24 | マクロジェニクス，インコーポレーテッド | 共有結合型ダイアボディとその使用 |
| US9284375B2 (en) | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| US11254748B2 (en) | 2005-04-15 | 2022-02-22 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| JP5144499B2 (ja) | 2006-03-31 | 2013-02-13 | 中外製薬株式会社 | 二重特異性抗体を精製するための抗体改変方法 |
| EP4793360A2 (en) | 2006-03-31 | 2026-08-19 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| EP3127921A1 (en) | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substition in cdr |
| ES2687808T3 (es) | 2007-09-26 | 2018-10-29 | Chugai Seiyaku Kabushiki Kaisha | Región constante de anticuerpo modificado |
| TW201920257A (zh) | 2008-04-11 | 2019-06-01 | 日商中外製藥股份有限公司 | 重複結合複數個抗原的抗原結合分子 |
| TWI544077B (zh) | 2009-03-19 | 2016-08-01 | 中外製藥股份有限公司 | Antibody constant region change body |
| JP5717624B2 (ja) | 2009-03-19 | 2015-05-13 | 中外製薬株式会社 | 抗体定常領域改変体 |
| BR112012004697B8 (pt) * | 2009-09-01 | 2021-05-25 | Genentech Inc | método para purificar um polipeptídeo compreendendo uma região ch2/ch3 |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| US10150808B2 (en) | 2009-09-24 | 2018-12-11 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
| AU2010336277B2 (en) * | 2009-12-25 | 2015-02-19 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide modification method for purifying polypeptide multimers |
| US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| US20130045492A1 (en) * | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
| SG183149A1 (en) | 2010-02-08 | 2012-09-27 | Regeneron Pharma | Common light chain mouse |
| US20120021409A1 (en) * | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| EP2543730B1 (en) | 2010-03-04 | 2018-10-31 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| PT2560993T (pt) * | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| EP2598530A2 (en) | 2010-07-29 | 2013-06-05 | Xencor, Inc. | Antibodies with modified isoelectric points |
| EP2601298B1 (en) | 2010-08-02 | 2016-11-30 | Regeneron Pharmaceuticals, Inc. | Mice that make binding proteins comprising vl domains |
| ES2667100T3 (es) | 2010-08-02 | 2018-05-09 | Macrogenics, Inc. | Diacuerpos covalentes y sus usos |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| CN105859889B (zh) | 2010-11-17 | 2020-01-07 | 中外制药株式会社 | 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子 |
| JO3756B1 (ar) | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
| TWI736437B (zh) | 2010-11-30 | 2021-08-11 | 日商中外製藥股份有限公司 | 細胞傷害誘導治療劑 |
| TWI654203B (zh) | 2010-11-30 | 2019-03-21 | Chugai Seiyaku Kabushiki Kaisha | 具有鈣依存性的抗原結合能力之抗體 |
| SG10201609665PA (en) | 2011-02-25 | 2017-01-27 | Chugai Pharmaceutical Co Ltd | FcɣRIIb-SPECIFIC Fc ANTIBODY |
| TWI622597B (zh) | 2011-03-28 | 2018-05-01 | 賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| MX2013011366A (es) * | 2011-03-30 | 2014-05-12 | Chugai Pharmaceutical Co Ltd | Retencion de las moleculas de union al antigeno en el plasma sanguineo y metodo para modificar la inmunogenicidad. |
| US9376495B2 (en) | 2011-05-21 | 2016-06-28 | Macrogenics, Inc. | Deimmunized serum-binding domains and their use in extending serum half-life |
| WO2013002362A1 (ja) * | 2011-06-30 | 2013-01-03 | 中外製薬株式会社 | ヘテロ二量化ポリペプチド |
| UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| ES2872081T3 (es) | 2011-08-05 | 2021-11-02 | Regeneron Pharma | Ratones con cadena ligera universal humanizada |
| CA2791109C (en) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
| JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| EP4074833A1 (en) * | 2011-10-17 | 2022-10-19 | Regeneron Pharmaceuticals, Inc. | Restricted immunoglobulin heavy chain mice |
| IN2014CN03887A (enExample) | 2011-10-27 | 2015-10-16 | Genmab As | |
| BR112014010257A2 (pt) | 2011-10-31 | 2017-04-18 | Chugai Pharmaceutical Co Ltd | molécula de ligação ao antígeno tendo conjugação regulada entre cadeias pesadas e cadeias leves |
| US9574010B2 (en) | 2011-11-04 | 2017-02-21 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| SMT201800092T1 (it) | 2011-11-14 | 2018-03-08 | Regeneron Pharma | Composizioni e metodi per aumentare la massa muscolare e la forza muscolare antagonizzando specificamente gdf8 e/o activina a |
| AU2012340107B2 (en) | 2011-11-18 | 2017-06-15 | Regeneron Pharmaceuticals, Inc. | Polymer protein microparticles |
| KR20210074395A (ko) | 2011-11-30 | 2021-06-21 | 추가이 세이야쿠 가부시키가이샤 | 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약 |
| US9527927B2 (en) | 2011-12-20 | 2016-12-27 | Medimmune, Llc | Modified polypeptides for bispecific antibody scaffolds |
| EP4624490A3 (en) | 2012-02-09 | 2025-11-05 | Chugai Seiyaku Kabushiki Kaisha | Modified fc region of antibody |
| CA2865158C (en) | 2012-02-24 | 2022-11-01 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for promoting disappearance of antigen via fc.gamma.riib |
| MX2014010527A (es) | 2012-03-02 | 2014-10-14 | Regeneron Pharma | Anticuerpos humanos para toxinas de clostridium difficile. |
| JP2015509380A (ja) | 2012-03-06 | 2015-03-30 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 共通の軽鎖のマウス |
| EP3517548A1 (en) | 2012-03-13 | 2019-07-31 | NovImmune S.A. | Readily isolated bispecific antibodies with native immunoglobulin format |
| US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
| US9801362B2 (en) | 2012-03-16 | 2017-10-31 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing pH-sensitive immunoglobulin sequences |
| WO2013138681A1 (en) | 2012-03-16 | 2013-09-19 | Regeneron Pharmaceuticals, Inc. | Mice that produce antigen-binding proteins with ph-dependent binding characteristics |
| HUE037659T2 (hu) | 2012-03-16 | 2018-09-28 | Regeneron Pharma | Hisztidinmódosított könnyûlánc antitestek és genetikailag módosított rágcsálók ennek az elõállítására |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| WO2013157953A1 (en) | 2012-04-20 | 2013-10-24 | Merus B.V. | Methods and means for the production of ig-like molecules |
| MX360368B (es) | 2012-04-27 | 2018-10-29 | Bioatla Llc | Regiones de anticuerpo modificado y sus usos. |
| NZ703689A (en) | 2012-06-12 | 2016-05-27 | Regeneron Pharma | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
| EP4310191A3 (en) | 2012-06-14 | 2024-05-15 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing modified fc region |
| WO2014004586A1 (en) | 2012-06-25 | 2014-01-03 | Zymeworks Inc. | Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells |
| WO2014006217A1 (en) | 2012-07-06 | 2014-01-09 | Genmab B.V. | Dimeric protein with triple mutations |
| EP3632462A1 (en) | 2012-07-06 | 2020-04-08 | Genmab B.V. | Dimeric protein with triple mutations |
| US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| JO3462B1 (ar) | 2012-08-22 | 2020-07-05 | Regeneron Pharma | أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها |
| TWI855488B (zh) | 2012-08-24 | 2024-09-11 | 日商中外製藥股份有限公司 | FcγRIIb特異性Fc區域變異體 |
| JOP20200236A1 (ar) * | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| US20150239991A1 (en) * | 2012-09-25 | 2015-08-27 | Glenmark Pharmaceuticals S.A. | Purification of hetero-dimeric immunoglobulins |
| BR112015006824A2 (pt) | 2012-09-27 | 2017-07-04 | Merus B V | anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico |
| WO2014054804A1 (ja) | 2012-10-05 | 2014-04-10 | 協和発酵キリン株式会社 | ヘテロダイマータンパク質組成物 |
| CA2889951C (en) | 2012-11-02 | 2023-04-18 | Zymeworks Inc. | Crystal structures of heterodimeric fc domains |
| JP6506024B2 (ja) | 2012-11-05 | 2019-04-24 | 全薬工業株式会社 | 抗体又は抗体組成物の製造方法 |
| TWI864338B (zh) | 2012-11-14 | 2024-12-01 | 美商再生元醫藥公司 | 重組細胞表面捕捉蛋白質 |
| US9914785B2 (en) | 2012-11-28 | 2018-03-13 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
| MX385344B (es) | 2012-11-28 | 2025-03-18 | Zymeworks Bc Inc | Pares de cadena pesada-cadena ligera de inmunoglobulina modificados genéticamente y usos de estos. |
| CN105102618B (zh) | 2012-12-27 | 2018-04-17 | 中外制药株式会社 | 异源二聚化多肽 |
| MX387324B (es) | 2013-01-10 | 2025-03-18 | Genmab Bv | Variantes de regiones fc de igg1 de humano y usos de las mismas. |
| US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
| KR102391731B1 (ko) | 2013-01-14 | 2022-04-27 | 젠코어 인코포레이티드 | 신규한 이형이량체 단백질 |
| US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
| US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
| WO2014113510A1 (en) | 2013-01-15 | 2014-07-24 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| RS57582B1 (sr) | 2013-02-20 | 2018-11-30 | Regeneron Pharma | Nehumane životinje sa modifikovanim sekvencama imunoglobulinskog teškog lanca |
| US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
| KR20150126863A (ko) | 2013-03-13 | 2015-11-13 | 리제너론 파마슈티칼스 인코포레이티드 | 공통 경쇄 마우스 |
| HUE061977T2 (hu) | 2013-03-13 | 2023-09-28 | Regeneron Pharma | Korlátozott immumglobulin könnyûlánc-repertoárt expresszáló egerek |
| BR112015021979A2 (pt) | 2013-03-14 | 2017-08-29 | Regeneron Pharma | Anticorpos humanos para grem1 |
| CA2906566C (en) | 2013-03-14 | 2024-09-10 | Macrogenics, Inc. | Immunoreactive bispecific molecules at immune effector cells expressing an activation receptor |
| JP6285532B2 (ja) * | 2013-03-14 | 2018-02-28 | イー・エム・デイー・ミリポア・コーポレイシヨン | タンパク質ａに基づくクロマトグラフィを使用するタンパク質純度を増加させる方法 |
| EP3421495A3 (en) | 2013-03-15 | 2019-05-15 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
| US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
| KR102049990B1 (ko) | 2013-03-28 | 2019-12-03 | 삼성전자주식회사 | c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질 |
| SG11201508170TA (en) | 2013-04-02 | 2015-11-27 | Chugai Pharmaceutical Co Ltd | Fc REGION VARIANT |
| US11357866B2 (en) * | 2013-04-03 | 2022-06-14 | The Administrators Of The Tulane Educational Fund | Expression of HIV inhibitors by mesenchymal stem cells |
| CA2904806C (en) | 2013-04-29 | 2021-11-23 | F. Hoffmann-La Roche Ag | Human fcrn-binding modified antibodies and methods of use |
| CA2904805A1 (en) * | 2013-04-29 | 2014-11-06 | F. Hoffmann-La Roche Ag | Fc-receptor binding modified asymmetric antibodies and methods of use |
| TWI655207B (zh) | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| US11384149B2 (en) | 2013-08-09 | 2022-07-12 | Macrogenics, Inc. | Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof |
| UA116479C2 (uk) | 2013-08-09 | 2018-03-26 | Макродженікс, Інк. | БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ |
| EP2840091A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof |
| EP2839842A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
| EP3041865A2 (en) * | 2013-09-03 | 2016-07-13 | NovImmune S.A. | Readily isolated bispecific binding molecules with native format having mutated constant regions |
| CN104418947A (zh) * | 2013-09-11 | 2015-03-18 | 香港大学 | 抗her2和抗-igf-ir的双特异性抗体及其用途 |
| MY191512A (en) | 2013-09-18 | 2022-06-28 | Regeneron Pharma | Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same |
| CA2925256C (en) * | 2013-09-27 | 2023-08-15 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
| AP2016009222A0 (en) | 2013-11-04 | 2016-05-31 | Glenmark Pharmaceuticals Sa | Production of t cell retargeting hetero-dimeric immunoglobulins |
| CA2931299C (en) | 2013-11-20 | 2024-03-05 | Regeneron Pharmaceuticals, Inc. | Aplnr modulators and uses thereof |
| LT3074424T (lt) | 2013-11-27 | 2025-05-26 | Zymeworks Bc Inc. | Bispecifiniai antigeną surišantys konstruktai, nukreipti į her2 |
| HUE050159T2 (hu) | 2013-12-17 | 2020-11-30 | Genentech Inc | Anti-CD3 antitestek és alkalmazási eljárások |
| JP2017029001A (ja) * | 2013-12-19 | 2017-02-09 | 国立研究開発法人産業技術総合研究所 | プロテインｇの細胞膜外ドメインの新規な改変型タンパク質 |
| CN110903398B (zh) | 2014-01-15 | 2023-08-15 | 豪夫迈·罗氏有限公司 | 具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体 |
| CN110981957B (zh) | 2014-01-15 | 2024-12-24 | 豪夫迈·罗氏有限公司 | 具有改善的蛋白A结合作用的Fc区变体 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| EP3107565A4 (en) * | 2014-02-21 | 2017-08-23 | Regeneron Pharmaceuticals, Inc. | Methods, compositions and kits for cell specific modulation of target antigens |
| CA2941030C (en) | 2014-02-28 | 2025-05-13 | Merus N.V. | ANTIBODIES THAT BIND TO EGFR AND ERBB3 |
| DK3805268T3 (da) | 2014-02-28 | 2025-01-20 | Merus Nv | Antistof, der binder erbb-2 og erbb-3 |
| TWI754319B (zh) * | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| AU2015230938C1 (en) | 2014-03-21 | 2021-10-14 | Regeneron Pharmaceuticals, Inc. | Non-human animals that make single domain binding proteins |
| SG10201808083VA (en) | 2014-03-21 | 2018-10-30 | Regeneron Pharma | Vl antigen binding proteins exhibiting distinct binding characteristics |
| PL3122781T3 (pl) | 2014-03-28 | 2020-06-15 | Xencor, Inc. | Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3 |
| JO3701B1 (ar) | 2014-05-23 | 2021-01-31 | Regeneron Pharma | مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي |
| LT3148579T (lt) | 2014-05-28 | 2021-05-25 | Agenus Inc. | Anti-gitr antikūnai ir jų panaudojimo būdai |
| DK3107938T3 (da) | 2014-05-28 | 2022-07-11 | Zymeworks Inc | Modificerede, antigenbindende polypeptidkonstrukter og anvendelser heraf |
| US10647768B2 (en) | 2014-05-29 | 2020-05-12 | Macrogenics, Inc. | Multi-chain polypeptide-containing tri-specific binding molecules |
| AR101262A1 (es) * | 2014-07-26 | 2016-12-07 | Regeneron Pharma | Plataforma de purificación para anticuerpos biespecíficos |
| WO2016019969A1 (en) | 2014-08-08 | 2016-02-11 | Ludwig-Maximilians-Universität München | Subcutaneously administered bispecific antibodies for use in the treatment of cancer |
| MA40579A (fr) | 2014-09-12 | 2016-03-17 | Genentech Inc | Anticorps anti-cll-1 et immunoconjugués |
| WO2016054101A1 (en) | 2014-09-29 | 2016-04-07 | Duke University | Bispecific molecules comprising an hiv-1 envelope targeting arm |
| US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
| MA40894A (fr) * | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
| PT3215528T (pt) * | 2014-11-06 | 2019-10-11 | Hoffmann La Roche | Variantes da região fc com ligação modificada ao fcrn e métodos de utilização |
| RU2713131C1 (ru) | 2014-11-06 | 2020-02-03 | Ф. Хоффманн-Ля Рош Аг | ВАРИАНТЫ Fc-ОБЛАСТИ С МОДИФИЦИРОВАННЫМИ СВОЙСТВАМИ СВЯЗЫВАНИЯ FcRn И БЕЛКА А |
| ES2809455T3 (es) | 2014-11-17 | 2021-03-04 | Regeneron Pharma | Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20 |
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| JP6696982B2 (ja) | 2014-11-26 | 2020-05-20 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ３および腫瘍抗原に結合するヘテロ二量体抗体 |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| HK1245171A1 (zh) | 2014-11-26 | 2018-08-24 | Xencor, Inc. | 结合cd3和cd38的异二聚体抗体 |
| ES2717308T3 (es) | 2014-12-06 | 2019-06-20 | Gemoab Monoclonals Gmbh | Células madre pluri- o multi-potentes genéticamente modificadas y sus usos |
| TWI701258B (zh) | 2014-12-19 | 2020-08-11 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
| US10428155B2 (en) | 2014-12-22 | 2019-10-01 | Xencor, Inc. | Trispecific antibodies |
| EP3789039A1 (en) | 2014-12-22 | 2021-03-10 | The Rockefeller University | Anti-mertk agonistic antibodies and uses thereof |
| TWI710573B (zh) | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | 抗伊波拉病毒醣蛋白之人類抗體 |
| US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
| KR102618312B1 (ko) | 2015-03-17 | 2023-12-28 | 메모리얼 슬로안 케터링 캔서 센터 | 항muc16 항체 및 그의 용도 |
| CN107438622A (zh) | 2015-03-19 | 2017-12-05 | 瑞泽恩制药公司 | 选择结合抗原的轻链可变区的非人动物 |
| TWI735433B (zh) | 2015-03-27 | 2021-08-11 | 美商再生元醫藥公司 | 偵測生物污染物之組成物及方法 |
| DK3277725T3 (da) | 2015-03-30 | 2021-01-11 | Regeneron Pharma | Konstante tungkædeområder med reduceret binding til FC-gammareceptorer |
| JP7082484B2 (ja) | 2015-04-01 | 2022-06-08 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| WO2016168613A1 (en) | 2015-04-15 | 2016-10-20 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with gdf8 inhibitors |
| EP3294775B1 (en) | 2015-05-12 | 2021-07-14 | Regeneron Pharmaceuticals, Inc. | Multimeric protein purity determination |
| DK3303394T3 (da) | 2015-05-29 | 2020-07-06 | Agenus Inc | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf |
| KR20250091329A (ko) | 2015-06-15 | 2025-06-20 | 누맙 세러퓨틱스 아게 | 이종 이량체 다중 특이적 항체 포맷 |
| TW201718647A (zh) | 2015-06-16 | 2017-06-01 | 建南德克公司 | 抗-cll-1抗體及使用方法 |
| AU2016284871B2 (en) | 2015-06-23 | 2022-09-29 | Innate Pharma | Multispecific NK engager proteins |
| JP6993958B2 (ja) | 2015-07-06 | 2022-02-04 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 多重特異性抗原結合分子およびその使用 |
| EP3319996B1 (en) | 2015-07-09 | 2024-01-03 | Genmab A/S | Bispecific and multispecific antibodies and method for isolation of such |
| WO2017010874A1 (en) | 2015-07-10 | 2017-01-19 | Merus N.V. | Human cd3 binding antibody |
| CA2991805A1 (en) | 2015-07-10 | 2017-01-19 | Genmab A/S | Axl-specific antibody-drug conjugates for cancer treatment |
| JOP20160154B1 (ar) | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
| TW202440903A (zh) | 2015-08-04 | 2024-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法（一） |
| AU2016312259B2 (en) | 2015-08-26 | 2018-12-06 | Bison Therapeutics Inc. | Multispecific antibody platform and related methods |
| US11091559B2 (en) | 2015-08-27 | 2021-08-17 | Celldex Therapeutics, Inc. | Anti-ALK antibodies and methods for use thereof |
| JP6869987B2 (ja) | 2015-09-01 | 2021-05-12 | アジェナス インコーポレイテッド | 抗ｐｄ−１抗体及びその使用方法 |
| MY195059A (en) | 2015-09-23 | 2023-01-05 | Regeneron Pharma | Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof |
| CN108283001B (zh) | 2015-10-08 | 2022-08-19 | 酵活有限公司 | 包含κ和λ轻链的抗原结合多肽构建体及其用途 |
| TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| JP7296728B2 (ja) | 2015-10-23 | 2023-06-23 | メルス ナムローゼ フェンノートシャップ | 癌の成長を抑制する結合分子 |
| WO2017079768A1 (en) | 2015-11-08 | 2017-05-11 | Genentech, Inc. | Methods of screening for multispecific antibodies |
| MX2018006333A (es) | 2015-12-01 | 2018-08-01 | Genmab Bv | Anticuerpos anti-receptor de muerte 5 (dr5) y metodos de uso de los mismos. |
| EP3387013B1 (en) | 2015-12-07 | 2022-06-08 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and psma |
| ES2954153T3 (es) | 2015-12-22 | 2023-11-20 | Regeneron Pharma | Combinación de anticuerpos anti-PD-1 y anticuerpos biespecíficos anti-CD20/anti-CD3 para tratar el cáncer |
| SG11201803989WA (en) * | 2015-12-28 | 2018-06-28 | Chugai Pharmaceutical Co Ltd | Method for promoting efficiency of purification of fc region-containing polypeptide |
| GB201602156D0 (en) * | 2016-02-05 | 2016-03-23 | Jones Philip C And Boku University Of Natural Resources And Life Sciences | Heterodimers and purification thereof |
| EP3431102A4 (en) | 2016-03-14 | 2019-09-25 | Chugai Seiyaku Kabushiki Kaisha | CELL DAMAGING THERAPEUTIC MEDICAMENT FOR USE IN CANCER THERAPY |
| US11291721B2 (en) | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| BR112018071283A2 (pt) * | 2016-04-20 | 2019-02-12 | Regeneron Pharma | célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, método, e, método para produção de uma proteína de ligação a antígeno. |
| US11530277B2 (en) | 2016-04-20 | 2022-12-20 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
| WO2017190079A1 (en) | 2016-04-28 | 2017-11-02 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| AU2017255077B2 (en) | 2016-04-28 | 2024-05-16 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing preparation |
| JP7031934B2 (ja) | 2016-05-11 | 2022-03-08 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックス |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| EP3455241B1 (en) | 2016-05-11 | 2022-02-23 | Cytiva BioProcess R&D AB | Method of cleaning and/or sanitizing a separation matrix |
| JP7122974B2 (ja) | 2016-05-11 | 2022-08-22 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 変異免疫グロブリン結合ポリペプチド |
| WO2017194592A1 (en) | 2016-05-11 | 2017-11-16 | Ge Healthcare Bioprocess R&D Ab | Method of storing a separation matrix |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| TWI822521B (zh) | 2016-05-13 | 2023-11-11 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
| SG10202102885UA (en) | 2016-05-20 | 2021-05-28 | Regeneron Pharma | Methods for breaking immunological tolerance using multiple guide rnas |
| KR102543118B1 (ko) | 2016-05-27 | 2023-06-14 | 아게누스 인코포레이티드 | 항-tim-3 항체 및 이의 사용 방법 |
| IL263481B2 (en) | 2016-06-14 | 2024-06-01 | Regeneron Pharma | Anti-c5 antibodies and uses thereof |
| CA3026151A1 (en) | 2016-06-14 | 2017-12-21 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
| RU2019102008A (ru) | 2016-06-28 | 2020-07-28 | Ксенкор, Инк. | Гетеродимерные антитела, которые связывают рецептор соматостатина 2-го типа |
| MA45554A (fr) | 2016-07-01 | 2019-05-08 | Resolve Therapeutics Llc | Fusions de binucléase optimisées. |
| WO2018007999A1 (en) | 2016-07-08 | 2018-01-11 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
| TW201815821A (zh) | 2016-07-18 | 2018-05-01 | 美商再生元醫藥公司 | 抗茲卡病毒抗體及使用方法 |
| WO2018039131A1 (en) | 2016-08-22 | 2018-03-01 | Protiva Biotherapeutics, Inc. | Anti-pd-1 antibodies, or fragments thereof, for treating hepatitis b |
| US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| KR102520731B1 (ko) | 2016-09-23 | 2023-04-14 | 리제너론 파아마슈티컬스, 인크. | 항-steap2 항체, 항체-약물 컨쥬게이트, 및 steap2 및 cd3에 결합하는 이중특이적 항원-결합 분자, 및 이의 용도 |
| KR102531251B1 (ko) | 2016-09-23 | 2023-05-15 | 리제너론 파아마슈티컬스, 인크. | 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체 |
| US12448411B2 (en) | 2016-09-30 | 2025-10-21 | Cytiva Bioprocess R&D Ab | Separation method |
| KR20230133934A (ko) | 2016-10-11 | 2023-09-19 | 아게누스 인코포레이티드 | 항-lag-3 항체 및 이의 사용 방법 |
| MX2019004327A (es) | 2016-10-14 | 2019-10-14 | Xencor Inc | Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1. |
| EP3535291A1 (en) | 2016-11-01 | 2019-09-11 | Genmab B.V. | Polypeptide variants and uses thereof |
| EP3535294B1 (en) | 2016-11-07 | 2025-02-12 | Neuracle Science Co., Ltd. | Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof |
| EP3541843A1 (en) | 2016-11-15 | 2019-09-25 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| IL307242B1 (en) | 2016-12-07 | 2026-07-01 | Agenus Inc | Anti-CTLA-4 antibodies and methods of using them |
| EP3559035A1 (en) | 2016-12-21 | 2019-10-30 | TeneoBio, Inc. | Anti-bcma heavy chain-only antibodies |
| EP3559032A1 (en) | 2016-12-23 | 2019-10-30 | Innate Pharma | Heterodimeric antigen binding proteins |
| TW202311284A (zh) | 2017-01-03 | 2023-03-16 | 美商再生元醫藥公司 | 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體 |
| TW201837174A (zh) | 2017-02-07 | 2018-10-16 | 日商第一三共股份有限公司 | 抗ｇｐｒｃ５ｄ抗體及包含該抗體之分子 |
| BR112019015900A2 (pt) | 2017-02-10 | 2020-04-07 | Genmab B.V. | polipeptídeo, métodos para aumentar a atividade agonística de um polipeptídeo, para aumentar a atividade de cdc de um polipeptídeo e de tratamento de um indivíduo tendo uma doença, composição, kit de partes, e, uso de um polipeptídeo ou uma composição |
| BR112019016336A2 (pt) | 2017-02-10 | 2020-03-31 | Regeneron Pharmaceuticals, Inc. | Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto. |
| WO2018151820A1 (en) | 2017-02-16 | 2018-08-23 | Elstar Therapeutics, Inc. | Multifunctional molecules comprising a trimeric ligand and uses thereof |
| WO2018151841A1 (en) | 2017-02-17 | 2018-08-23 | Sanofi | Multispecific binding molecules having specificity to dystroglycan and laminin-2 |
| CN110997714B (zh) | 2017-02-17 | 2024-05-03 | 赛诺菲 | 对肌营养不良蛋白聚糖和层粘连蛋白-2具有特异性的多特异性结合分子 |
| KR102654105B1 (ko) | 2017-02-17 | 2024-04-04 | 사노피 | 디스트로글리칸 및 라미닌-2에 대한 특이성을 갖는 다중특이적 결합 분자 |
| EP3589650A1 (en) | 2017-03-02 | 2020-01-08 | Novartis AG | Engineered heterodimeric proteins |
| EP3601351A1 (en) | 2017-03-27 | 2020-02-05 | Celgene Corporation | Methods and compositions for reduction of immunogenicity |
| JP7737220B2 (ja) | 2017-03-31 | 2025-09-10 | メルス ナムローゼ フェンノートシャップ | ＮＲＧ１融合遺伝子を有する細胞の処置における使用のためのＥｒｂＢ－２及びＥｒｂＢ３結合二重特異性抗体 |
| CN119285787A (zh) | 2017-03-31 | 2025-01-10 | 健玛保控股有限公司 | 双特异性抗cd37抗体、单克隆抗cd37抗体及其使用方法 |
| JP7209298B2 (ja) | 2017-03-31 | 2023-01-20 | 公立大学法人奈良県立医科大学 | 血液凝固第ｖｉｉｉ因子の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｉｘ因子異常症の予防および／または治療に用いられる医薬組成物 |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| MY200973A (en) | 2017-04-11 | 2024-01-26 | Inhibrx Inc | Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same |
| BR112019017241A2 (pt) | 2017-04-13 | 2020-04-14 | Agenus Inc. | anticorpos anti-cd137 e métodos de uso dos mesmos |
| WO2018193427A1 (en) | 2017-04-21 | 2018-10-25 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
| LT3618863T (lt) | 2017-05-01 | 2023-10-10 | Agenus Inc. | Anti-tigit antikūnai ir jų panaudojimo būdai |
| EP3625264B9 (en) | 2017-05-17 | 2023-10-25 | Merus N.V. | Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer |
| EP3630836A1 (en) | 2017-05-31 | 2020-04-08 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
| KR20200014379A (ko) * | 2017-06-05 | 2020-02-10 | 얀센 바이오테크 인코포레이티드 | 비대칭 ch2-ch3 영역 돌연변이를 갖는 조작된 다중특이성 항체 및 다른 다량체 단백질 |
| US12098203B2 (en) | 2017-06-05 | 2024-09-24 | Numab Therapeutics AG | Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA |
| EP3635005A1 (en) | 2017-06-07 | 2020-04-15 | Genmab B.V. | Therapeutic antibodies based on mutated igg hexamers |
| AU2018281280B2 (en) | 2017-06-07 | 2024-12-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for internalizing enzymes |
| CN118853581A (zh) | 2017-06-21 | 2024-10-29 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(CARs)、组合物及其使用方法 |
| GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
| WO2019006034A1 (en) | 2017-06-27 | 2019-01-03 | Regeneron Pharmaceuticals, Inc. | NON-HUMAN ANIMALS COMPRISING A HUMANIZED ASGR1 LOCUS |
| SI3645551T1 (sl) | 2017-06-27 | 2024-06-28 | Regeneron Pharmaceuticals, Inc. | S tropizmi spremenjeni rekombinantni virusni vektorji in njihova uporaba za tarčni vnos genetskega materiala v človeške celice |
| BR112019027729A2 (pt) | 2017-06-27 | 2020-08-18 | Neuracle Science Co., Ltd | anticorpos anti-fam19a5 e seus usos |
| WO2019005756A1 (en) | 2017-06-28 | 2019-01-03 | The Rockefeller University | CONJUGATES AGONIST ANTIBODY ANTI-MERTK-MEDICINE |
| IL299348B2 (en) | 2017-06-28 | 2025-05-01 | Regeneron Pharma | Antigen-binding proteins against human papillomavirus and methods of using them |
| AU2018291497A1 (en) | 2017-06-30 | 2020-01-16 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains |
| KR20210084695A (ko) | 2017-07-06 | 2021-07-07 | 리제너론 파마슈티칼스 인코포레이티드 | 당단백질을 만들기 위한 세포 배양 과정 |
| CN111566214B (zh) * | 2017-07-06 | 2024-03-08 | 日东纺绩株式会社 | 抗人IgG4单克隆抗体及利用该抗体的人IgG4测定试剂 |
| TWI865430B (zh) | 2017-07-24 | 2024-12-11 | 美商再生元醫藥公司 | 穩定化之抗體組合物及其製法 |
| TWI799432B (zh) | 2017-07-27 | 2023-04-21 | 美商再生元醫藥公司 | 抗ctla-4抗體及其用途 |
| JP7801095B2 (ja) * | 2017-08-01 | 2026-01-16 | エイビー セラピューティクス インコーポレイテッド | 二重特異性抗体およびその使用 |
| CN118126157A (zh) | 2017-08-03 | 2024-06-04 | 美国安进公司 | 白介素-21突变蛋白和治疗方法 |
| KR20250020679A (ko) | 2017-08-04 | 2025-02-11 | 젠맵 에이/에스 | Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도 |
| RS66708B9 (sr) | 2017-08-09 | 2025-08-29 | Merus Nv | Antitela koja se vezuju za egfr i cmet |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| CN111315767B (zh) | 2017-08-22 | 2025-03-18 | 萨纳生物有限责任公司 | 可溶性干扰素受体及其用途 |
| US10640504B2 (en) | 2017-09-08 | 2020-05-05 | Amgen Inc. | Inhibitors of KRAS G12C and methods of using the same |
| WO2019055841A1 (en) * | 2017-09-14 | 2019-03-21 | Denali Therapeutics Inc. | ANTI-TREM2 ANTIBODIES AND METHODS OF USE |
| WO2019067875A1 (en) | 2017-09-29 | 2019-04-04 | Regeneron Pharmaceuticals, Inc. | NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS AND METHODS OF USE |
| BR112020004977A2 (pt) | 2017-09-29 | 2020-10-06 | Regeneron Pharmaceuticals, Inc. | moléculas de ligação de antígenos biespecíficas que ligam antígeno alvo de staphyocococcus e componente de complemento e usos dos mesmos |
| KR102956517B1 (ko) | 2017-10-04 | 2026-04-23 | 암젠 인크 | 트랜스타이레틴 면역글로불린 융합 |
| WO2019077092A1 (en) | 2017-10-20 | 2019-04-25 | F. Hoffmann-La Roche Ag | METHOD FOR GENERATING MULTISPECIFIC ANTIBODIES FROM MONOSPECIFIC ANTIBODIES |
| IL274071B2 (en) | 2017-10-30 | 2025-10-01 | Hoffmann La Roche | Method for generating in vivo multispecific antibodies from monospecific antibodies |
| CN111315772A (zh) | 2017-10-31 | 2020-06-19 | 斯塔顿生物技术有限公司 | 抗apoc3抗体及其使用方法 |
| KR20260090008A (ko) | 2017-11-01 | 2026-06-16 | 추가이 세이야쿠 가부시키가이샤 | 생물 활성이 저하된 항체 배리언트 및 아이소폼 |
| AU2018358804A1 (en) * | 2017-11-02 | 2020-04-09 | Bayer Aktiengesellschaft | Bispecific antibodies binding ALK-1 and BMPR-2 |
| CN117756946A (zh) * | 2017-11-03 | 2024-03-26 | 莱蒂恩技术公司 | 用于用抗ror1免疫治疗来治疗癌症的组合物和方法 |
| AU2018366199A1 (en) | 2017-11-08 | 2020-05-28 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
| US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| EP3713959A1 (en) | 2017-11-21 | 2020-09-30 | Innate Pharma | Multispecific antigen binding proteins |
| JP7361031B2 (ja) | 2017-11-30 | 2023-10-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物 |
| AU2018383751B2 (en) | 2017-12-13 | 2025-05-08 | Regeneron Pharmaceuticals, Inc. | Anti-C5 antibody combinations and uses thereof |
| JP7765181B2 (ja) | 2017-12-19 | 2025-11-06 | ゼンコア インコーポレイテッド | 改変されたｉｌ－２ ｆｃ融合タンパク質 |
| CN111448217A (zh) | 2017-12-22 | 2020-07-24 | 阿根思公司 | 双特异性抗原结合构建体 |
| US20190194298A1 (en) | 2017-12-22 | 2019-06-27 | Regeneron Pharmaceuticals, Inc. | System and method for characterizing drug product impurities |
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| MX2020007291A (es) | 2018-01-12 | 2020-09-10 | Amgen Inc | Anticuerpos anti-pd-1 y metodos de tratamiento. |
| US12649798B2 (en) | 2018-01-24 | 2026-06-09 | Genmab B.V. | Polypeptide variants and uses thereof |
| SG11202006379UA (en) | 2018-01-26 | 2020-07-29 | Regeneron Pharma | Human antibodies to influenza hemagglutinin |
| CA3085177A1 (en) | 2018-01-31 | 2019-08-08 | Regeneron Pharamaceuticals, Inc. | System and method for characterizing size and charge variant drug product impurities |
| TW202411650A (zh) | 2018-02-01 | 2024-03-16 | 美商再生元醫藥公司 | 治療性單株抗體之品質屬性的定量及模型化 |
| JP7539834B2 (ja) | 2018-02-01 | 2024-08-26 | メモリアル スローン ケタリング キャンサー センター | ガレクチン－３に対する抗体及びその使用方法 |
| TW202311746A (zh) | 2018-02-02 | 2023-03-16 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| CN112040985A (zh) | 2018-02-07 | 2020-12-04 | 瑞泽恩制药公司 | 用于递送治疗性蛋白质的方法和组合物 |
| CR20200391A (es) | 2018-02-08 | 2020-10-19 | Genentech Inc | Moléculas biespecíficas de unión al antígeno y métodos de uso |
| GB201802487D0 (en) | 2018-02-15 | 2018-04-04 | Argenx Bvba | Cytokine combination therapy |
| AU2019227531B2 (en) | 2018-02-28 | 2025-01-30 | Regeneron Pharmaceuticals, Inc. | Systems and methods for identifying viral contaminants |
| IL276921B2 (en) | 2018-03-01 | 2025-12-01 | Regeneron Pharma | Methods for altering body composition |
| EP3765517A1 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| EP3765516A2 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
| US11054389B2 (en) | 2018-03-19 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US12259355B2 (en) | 2018-03-19 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US12253490B2 (en) | 2018-03-19 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| EP4534560A3 (en) | 2018-03-24 | 2025-06-11 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof |
| CN112469477A (zh) | 2018-04-04 | 2021-03-09 | Xencor股份有限公司 | 与成纤维细胞活化蛋白结合的异源二聚体抗体 |
| TW202010757A (zh) | 2018-04-11 | 2020-03-16 | 美商英伊布里克斯公司 | 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途 |
| KR20210003814A (ko) | 2018-04-18 | 2021-01-12 | 젠코어 인코포레이티드 | IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질 |
| CA3097593A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
| JP7328990B2 (ja) | 2018-04-30 | 2023-08-17 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｈｅｒ２及び／またはａｐｌｐ２に結合する抗体及び二重特異性抗原結合分子、ならびにそれらのコンジュゲート及び使用 |
| MX2020011552A (es) | 2018-05-03 | 2020-11-24 | Genmab Bv | Combinaciones de variantes de anticuerpos y usos de las mismas. |
| KR20240056644A (ko) | 2018-05-10 | 2024-04-30 | 주식회사 뉴라클사이언스 | 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리 및 그의 사용 방법 |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| EP3793591A1 (en) | 2018-05-17 | 2021-03-24 | Regeneron Pharmaceuticals, Inc. | Anti-cd63 antibodies, conjugates, and uses thereof |
| SG11202011461TA (en) | 2018-06-01 | 2020-12-30 | Compugen Ltd | Anti-pvrig/anti-tigit bispecific antibodies and methods of use |
| TWI848953B (zh) | 2018-06-09 | 2024-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
| EA202190056A1 (ru) | 2018-06-19 | 2021-05-28 | Ридженерон Фармасьютикалз, Инк. | АНТИТЕЛА ПРОТИВ ФАКТОРА XII/XIIa И ИХ ПРИМЕНЕНИЕ |
| TW202504917A (zh) | 2018-06-21 | 2025-02-01 | 美商再生元醫藥公司 | 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症之方法 |
| JP7513530B2 (ja) | 2018-06-22 | 2024-07-09 | ジェンマブ ホールディング ビー．ブイ． | 抗ｃｄ３７抗体および抗ｃｄ２０抗体、組成物、ならびにそれらの使用方法 |
| US12247065B2 (en) | 2018-06-22 | 2025-03-11 | Genmab A/S | Method for producing a controlled mixture of two or more different antibodies |
| CN112424358B (zh) | 2018-06-26 | 2025-07-01 | 协和麒麟株式会社 | 与细胞粘附分子3结合的抗体 |
| CA3104997A1 (en) | 2018-06-26 | 2020-01-02 | Kyowa Kirin Co., Ltd. | Antibody binding to chondroitin sulfate proteoglycan 5 |
| MX2020013923A (es) | 2018-06-29 | 2021-03-29 | Apitbio Inc | Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos. |
| WO2020010250A2 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| MX2021000239A (es) * | 2018-07-10 | 2021-03-25 | Regeneron Pharma | Modificacion de moleculas de union para minimizar interacciones preexistentes. |
| EP3820900A1 (en) | 2018-07-13 | 2021-05-19 | Genmab A/S | Variants of cd38 antibody and uses thereof |
| TWI902667B (zh) | 2018-07-13 | 2025-11-01 | 美商再生元醫藥公司 | 醣基化肽之偵測及定量 |
| MA53123A (fr) | 2018-07-13 | 2021-05-19 | Genmab As | Thérapie à médiation par trogocytose utilisant des anticorps cd38 |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| WO2020023553A1 (en) | 2018-07-24 | 2020-01-30 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| US20200064353A1 (en) | 2018-08-13 | 2020-02-27 | Regeneron Pharmaceuticals, Inc. | Therapeutic Protein Selection in Simulated In Vivo Conditions |
| SG11202101369XA (en) | 2018-08-17 | 2021-03-30 | Regeneron Pharma | Method and chromatography system for determining amount and purity of a multimeric protein |
| JP2021534408A (ja) | 2018-08-17 | 2021-12-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｄｅ ｎｏｖｏタンパク質シークエンシングのための方法 |
| MX2021002165A (es) | 2018-08-23 | 2021-07-16 | Regeneron Pharma | Anticuerpos anti-fc épsilon-r1 alfa (fcer1a), moléculas de unión a antígeno biespecíficas que se unen a fcer1a y cd3 y usos de éstos. |
| MY204234A (en) | 2018-08-27 | 2024-08-16 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
| WO2020047067A1 (en) | 2018-08-30 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing protein complexes |
| ES3009025T3 (en) | 2018-08-31 | 2025-03-25 | Regeneron Pharma | Dosing strategy that mitigates cytokine release syndrome for cd3/cd20 bispecific antibodies |
| GB2576914A (en) | 2018-09-06 | 2020-03-11 | Kymab Ltd | Antigen-binding molecules comprising unpaired variable domains produced in mammals |
| JP2022504287A (ja) | 2018-10-03 | 2022-01-13 | スターテン・バイオテクノロジー・ベー・フェー | ヒト及びカニクイザルａｐｏｃ３に特異的な抗体、並びにその使用の方法 |
| KR102884523B1 (ko) | 2018-10-03 | 2025-11-10 | 젠코어 인코포레이티드 | IL-12 이종이량체 Fc-융합 단백질 |
| AU2019354105A1 (en) | 2018-10-04 | 2021-04-29 | Genmab Holding B.V. | Pharmaceutical compositions comprising bispecific anti-CD37 antibodies |
| US12590169B2 (en) | 2018-10-11 | 2026-03-31 | Inhibrx Biosciences, Inc. | 5T4 single domain antibodies and therapeutic compositions thereof |
| AU2019356573B2 (en) | 2018-10-11 | 2025-12-18 | Inhibrx Biosciences, Inc. | PD-1 single domain antibodies and therapeutic compositions thereof |
| CN113166261A (zh) | 2018-10-11 | 2021-07-23 | 印希比股份有限公司 | B7h3单域抗体及其治疗性组合物 |
| JP7611820B2 (ja) | 2018-10-11 | 2025-01-10 | インヒブルクス バイオサイエンシズ インコーポレイテッド | Ｄｌｌ３シングルドメイン抗体およびその治療用組成物 |
| CA3115102A1 (en) | 2018-10-23 | 2020-04-30 | Regeneron Pharmaceuticals, Inc. | Anti-npr1 antibodies and uses thereof |
| WO2020086893A1 (en) | 2018-10-25 | 2020-04-30 | Regeneron Pharmaceuticals, Inc. | Methods for analysis of viral capsid protein composition |
| WO2020087065A1 (en) * | 2018-10-26 | 2020-04-30 | Teneobio, Inc. | Heavy chain antibodies binding to cd38 |
| CA3116717A1 (en) | 2018-10-31 | 2020-05-07 | Regeneron Pharmaceuticals, Inc. | Method and system of identifying and quantifying a protein |
| CN113454111A (zh) | 2018-11-06 | 2021-09-28 | 健玛保 | 抗体配制剂 |
| JP7463366B2 (ja) | 2018-11-20 | 2024-04-08 | タケダ ワクチン，インコーポレイテッド | 新規の抗ジカウイルス抗体及びその使用 |
| CA3110377A1 (en) | 2018-11-21 | 2020-05-28 | Regeneron Pharmaceuticals, Inc. | Anti-staphylococcus antibodies and uses thereof |
| US11249089B2 (en) | 2018-12-12 | 2022-02-15 | Regeneron Pharmaceuticals, Inc. | System and method of analysis of a protein using liquid chromatography-mass spectrometry |
| TWI874341B (zh) | 2018-12-18 | 2025-03-01 | 美商健生生物科技公司 | 產生異二聚體抗體之方法 |
| US11782023B2 (en) * | 2018-12-19 | 2023-10-10 | Regeneron Pharmaceuticals, Inc. | Ce-western applications for antibody development |
| GB201820687D0 (en) | 2018-12-19 | 2019-01-30 | Kymab Ltd | Antagonists |
| WO2020132024A1 (en) * | 2018-12-19 | 2020-06-25 | Regeneron Pharmaceuticals, Inc. | Bispecific anti-muc16 x anti-cd28 antibodies and uses thereof |
| TWI772724B (zh) | 2018-12-21 | 2022-08-01 | 英商克馬伯有限公司 | 具有共同輕鏈的FIXaxFX雙專一性抗體 |
| JP7734075B2 (ja) | 2018-12-24 | 2025-09-04 | サノフイ | 疑似ｆａｂベースの多重特異性結合タンパク質 |
| CN113544145B (zh) * | 2018-12-24 | 2024-12-17 | 首尔大学校产学协力团 | 中和1型干扰素的fc融合蛋白及其用途 |
| MX2021004504A (es) | 2019-01-02 | 2021-10-01 | Neuracle Science Co Ltd | Anti-familia con similitud de secuencia 19, anticuerpos del miembro a5 y método de uso de los mismos. |
| JP2022517720A (ja) | 2019-01-16 | 2022-03-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ジスルフィド結合を特徴付けるための方法 |
| CN113660956B (zh) | 2019-01-28 | 2024-10-29 | Ab诊疗公司 | 双特异性抗体及其用途 |
| CA3126712A1 (en) | 2019-01-31 | 2020-08-06 | Regeneron Pharmaceuticals, Inc. | Native microfluidic ce-ms analysis of antibody charge heterogeneity |
| JP2022519631A (ja) | 2019-02-12 | 2022-03-24 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 補体および標的抗原に結合する二重特異性抗体を使用するための組成物および方法 |
| AU2020226893B2 (en) | 2019-02-21 | 2025-02-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| SG11202109056TA (en) | 2019-02-21 | 2021-09-29 | Marengo Therapeutics Inc | Multifunctional molecules that bind to calreticulin and uses thereof |
| JP7579795B2 (ja) | 2019-02-21 | 2024-11-08 | マレンゴ・セラピューティクス，インコーポレーテッド | ＮＫｐ３０に結合する抗体分子およびその使用 |
| SG11202109122SA (en) | 2019-02-21 | 2021-09-29 | Marengo Therapeutics Inc | Anti-tcr antibody molecules and uses thereof |
| WO2020172598A1 (en) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders |
| CN119735688A (zh) | 2019-02-26 | 2025-04-01 | 茵思博纳公司 | 高-亲和力抗-mertk抗体及其用途 |
| EP3930850A1 (en) | 2019-03-01 | 2022-01-05 | Xencor, Inc. | Heterodimeric antibodies that bind enpp3 and cd3 |
| EA202192422A1 (ru) | 2019-03-05 | 2021-12-09 | Ридженерон Фармасьютикалз, Инк. | Человеческий сывороточный альбумин в составах |
| EP3945800A1 (en) | 2019-04-03 | 2022-02-09 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for insertion of antibody coding sequences into a safe harbor locus |
| JP7506686B2 (ja) | 2019-04-04 | 2024-06-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化凝固因子１２遺伝子座を含む非ヒト動物 |
| MX2021012335A (es) | 2019-04-10 | 2021-11-12 | Regeneron Pharma | Anticuerpos humanos que se unen a ret y metodos de uso de los mismos. |
| US20220315661A1 (en) | 2019-05-09 | 2022-10-06 | Genmab B.V. | Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer |
| US20200393455A1 (en) | 2019-05-21 | 2020-12-17 | Regeneron Pharmaceuticals, Inc. | Methods for identifying and quantitating host cell protein |
| WO2020247452A1 (en) | 2019-06-04 | 2020-12-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use |
| PT3979790T (pt) | 2019-06-05 | 2026-05-05 | Regeneron Pharma | Roedores possuindo um reportrio limitado de cadeias leves lambda expressadas a partir do lcus kappa e suas utilizaes |
| CN113966343A (zh) | 2019-06-11 | 2022-01-21 | 瑞泽恩制药公司 | 结合PcrV的抗PcrV抗体、包含抗PcrV抗体的组合物及其使用方法 |
| AU2020293237A1 (en) | 2019-06-13 | 2022-01-06 | Regeneron Pharmaceuticals, Inc. | Methods for removing undesired components during multistage chromatographic processes |
| JP7743314B2 (ja) | 2019-06-21 | 2025-09-24 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｍｕｃ１６およびｃｄ３に結合する二重特異性抗原結合分子の４－１ｂｂ共刺激と組み合わせての使用 |
| EP3986933A1 (en) | 2019-06-21 | 2022-04-27 | Regeneron Pharmaceuticals, Inc. | Use of bispecific antigen-binding molecules that bind psma and cd3 in combination with 4-1bb co-stimulation |
| US20220324924A1 (en) | 2019-07-08 | 2022-10-13 | Amgen Inc. | Multispecific transthyretin immunoglobulin fusions |
| JP7359864B2 (ja) | 2019-07-10 | 2023-10-11 | 中外製薬株式会社 | クローディン６結合分子およびその使用 |
| GB201910900D0 (en) * | 2019-07-31 | 2019-09-11 | Scancell Ltd | Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof |
| CN114585651A (zh) | 2019-08-08 | 2022-06-03 | 再生元制药公司 | 新型抗原结合分子形式 |
| MX2022001942A (es) | 2019-08-15 | 2022-07-27 | Regeneron Pharma | Moléculas de union a antígeno multiespecíficas para el direcciónamiento célular y usos de las mismas. |
| TW202120537A (zh) | 2019-08-15 | 2021-06-01 | 美商健生生物科技公司 | 用於經改善的單鏈可變片段之材料及方法 |
| CN114585644A (zh) | 2019-08-30 | 2022-06-03 | 艾吉纳斯公司 | 抗cd96抗体及其使用方法 |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| JP7611908B2 (ja) | 2019-10-28 | 2025-01-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗血球凝集素抗体およびその使用方法 |
| AU2020379735A1 (en) | 2019-11-05 | 2022-05-26 | Regeneron Pharmaceuticals, Inc. | N-terminal SCFV multispecific binding molecules |
| JP7880817B2 (ja) | 2019-11-06 | 2026-06-26 | ジェンマブ ビー．ブイ． | 抗体変種の組み合わせおよびその使用 |
| WO2021108363A1 (en) | 2019-11-25 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Crispr/cas-mediated upregulation of humanized ttr allele |
| US11730793B2 (en) | 2019-11-25 | 2023-08-22 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous emulsions |
| WO2021113297A1 (en) | 2019-12-02 | 2021-06-10 | Regeneron Pharmaceuticals, Inc. | Peptide-mhc ii protein constructs and uses thereof |
| JP7693672B2 (ja) | 2019-12-06 | 2025-06-17 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体により多発性骨髄腫を治療する方法 |
| IL309560B2 (en) | 2019-12-06 | 2025-05-01 | Regeneron Pharma | Anti-VEGF protein preparations and methods for their production |
| WO2021116337A1 (en) | 2019-12-11 | 2021-06-17 | Cilag Gmbh International | Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof |
| IL293978A (en) | 2019-12-20 | 2022-08-01 | Regeneron Pharma | New il2 agonists and methods of using them |
| EP4141025A4 (en) | 2019-12-26 | 2024-04-24 | ABL Bio, Inc. | Method for purifying biologically active peptide by using protein a affinity chromatography |
| WO2021138474A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| EP4084821A4 (en) | 2020-01-03 | 2024-04-24 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
| CN115280151A (zh) | 2020-01-08 | 2022-11-01 | 瑞泽恩制药公司 | 使用氨基酸增强质谱分析中的信号 |
| MX2022008050A (es) | 2020-01-16 | 2022-07-27 | Genmab As | Formulaciones de anticuerpos anti cumulo de diferenciacion 38 (cd38) y usos de las mismas. |
| CA3165060C (en) | 2020-01-21 | 2023-06-20 | Yiming Zhao | Deglycosylation methods for electrophoresis of glycosylated proteins |
| MX2022009229A (es) | 2020-01-27 | 2022-08-16 | Regeneron Pharma | Cuantificacion en formato multiple por etiquetas de masa en tandem de modificaciones postraduccionales de proteinas. |
| WO2021154791A1 (en) | 2020-01-28 | 2021-08-05 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized pnpla3 locus and methods of use |
| EP4097129A1 (en) | 2020-01-29 | 2022-12-07 | Inhibrx, Inc. | Cd28 single domain antibodies and multivalent and multispecific constructs thereof |
| US11598756B2 (en) | 2020-01-30 | 2023-03-07 | Regeneron Pharmaceuticals, Inc. | Platform for native liquid chromatography-mass spectrometry |
| IL294907A (en) | 2020-01-31 | 2022-09-01 | Regeneron Pharma | High confidence compound identification by liquid chromatography-mass spectrometry |
| EP4099821A1 (en) | 2020-02-07 | 2022-12-14 | Regeneron Pharmaceuticals, Inc. | <smallcaps/>? ? ?klkb1? ? ? ? ?non-human animals comprising a humanizedlocus and methods of use |
| US11945872B2 (en) | 2020-02-11 | 2024-04-02 | Regeneron Pharmaceuticals, Inc. | Anti-ACVR1 antibodies and uses thereof |
| WO2021190980A1 (en) | 2020-03-22 | 2021-09-30 | Quadrucept Bio Limited | Multimers for viral strain evolution |
| US20230102342A1 (en) | 2020-03-23 | 2023-03-30 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use |
| JP7664943B2 (ja) | 2020-03-25 | 2025-04-18 | イーライ リリー アンド カンパニー | 多重特異性結合タンパク質およびそれを開発する方法 |
| CA3175577A1 (en) | 2020-03-30 | 2021-10-07 | Mie University | Bispecific antibody |
| JP2023522624A (ja) | 2020-04-14 | 2023-05-31 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 直交部分最小二乗によるクロマトグラフィ性能の紫外線モニタリング |
| AU2021261420A1 (en) | 2020-04-24 | 2022-12-01 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| MX2022013812A (es) | 2020-05-08 | 2022-12-15 | Regeneron Pharma | Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer. |
| WO2021228904A1 (en) | 2020-05-11 | 2021-11-18 | Academisch Medisch Centrum | Neutralizing antibodies binding to the spike protein of sars-cov-2 suitable for use in the treatment of covid-19, compositions comprising the same and uses thereof |
| MX2022014090A (es) | 2020-05-12 | 2023-02-27 | Regeneron Pharma | Anticuerpos antagonistas anti-glp1r y metodos de uso de los mismos. |
| KR20230009430A (ko) | 2020-05-12 | 2023-01-17 | 리제너론 파아마슈티컬스, 인크. | 신규 il10 효능제 및 그의 사용 방법 |
| EP4149632A1 (en) | 2020-05-14 | 2023-03-22 | Xencor, Inc. | Heterodimeric antibodies that bind msln and cd3 |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| EP4171215A2 (en) | 2020-06-26 | 2023-05-03 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ace2 locus |
| US20230293680A1 (en) | 2020-07-23 | 2023-09-21 | Genmab B.V. | A composition of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma |
| AU2021328375A1 (en) | 2020-08-18 | 2023-04-13 | Cephalon Llc | Anti-PAR-2 antibodies and methods of use thereof |
| US11919958B2 (en) | 2020-08-19 | 2024-03-05 | Xencor, Inc. | Anti-CD28 compositions |
| CN116249713A (zh) | 2020-08-20 | 2023-06-09 | 瑞泽恩制药公司 | 利用激活素a拮抗剂预防和治疗心功能不全和covid-19的方法 |
| JP2023539645A (ja) | 2020-08-26 | 2023-09-15 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｎｋｐ３０に結合する抗体分子およびその使用 |
| CA3190573A1 (en) | 2020-08-26 | 2022-03-03 | Andreas Loew | Methods of detecting trbc1 or trbc2 |
| AU2021331075A1 (en) | 2020-08-26 | 2023-04-06 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| KR20230058094A (ko) | 2020-08-31 | 2023-05-02 | 리제너론 파아마슈티컬스, 인크. | 세포 배양 성능을 개선하고 아스파라긴 서열 변이체를 완화하기 위한 아스파라긴 공급 전략 |
| US20220090060A1 (en) | 2020-09-11 | 2022-03-24 | Regeneron Pharmaceuticals, Inc. | Identification and production of antigen-specific antibodies |
| JP7905328B2 (ja) | 2020-09-18 | 2026-08-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｃｄ３８及び／又はｃｄ２８を結合する抗原結合分子及びその使用 |
| PH12023550779A1 (en) | 2020-09-28 | 2023-11-20 | Angitia Biomedicines Ltd | Anti-sclerostin constructs and uses thereof |
| US20230365714A1 (en) | 2020-10-02 | 2023-11-16 | Genmab A/S | Antibodies capable of binding to ror2 and bispecific antibodies binding to ror2 and cd3 |
| WO2022082030A2 (en) | 2020-10-15 | 2022-04-21 | Gritstone Bio, Inc. | Antigen-binding proteins and related methods of use |
| CA3198049A1 (en) | 2020-10-15 | 2022-04-21 | UCB Biopharma SRL | Binding molecules that multimerise cd45 |
| US11866502B2 (en) | 2020-10-22 | 2024-01-09 | Regeneron Pharmaceuticals, Inc. | Anti-FGFR2 antibodies and methods of use thereof |
| WO2022098638A2 (en) | 2020-11-04 | 2022-05-12 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| JP7716473B2 (ja) | 2020-11-04 | 2025-07-31 | ジェネンテック， インコーポレイテッド | 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬 |
| EP4240493A2 (en) | 2020-11-04 | 2023-09-13 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates |
| CN117120477A (zh) | 2020-11-10 | 2023-11-24 | 上海齐鲁制药研究中心有限公司 | 针对密蛋白18a2和cd3的双特异性抗体及其应用 |
| EP4251128A1 (en) | 2020-11-25 | 2023-10-04 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous membrane emulsification |
| CN114539416B (zh) * | 2020-11-26 | 2024-11-08 | 盛禾(中国)生物制药有限公司 | 一种双特异性抗体的层析纯化工艺 |
| IL303675A (en) | 2020-12-17 | 2023-08-01 | Regeneron Pharma | Production of protein thermal microgels |
| US12325752B2 (en) | 2020-12-18 | 2025-06-10 | Regeneron Pharmaceuticals, Inc. | Immunoglobulin proteins that bind to NPR1 agonists |
| CA3202429A1 (en) | 2020-12-20 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Methods for identification of scrambled disulfides in biomolecules |
| US20250223379A1 (en) * | 2021-01-11 | 2025-07-10 | Adimab, Llc | Variant ch3 domains engineered for preferential ch3 heterodimerization, multi-specific antibodies comprising the same, and methods of making thereof |
| WO2022155503A1 (en) | 2021-01-14 | 2022-07-21 | Gritstone Bio, Inc. | Multi-specific antibodies and methods of use |
| MX2023008527A (es) | 2021-01-20 | 2023-07-28 | Regeneron Pharma | Metodos para mejorar el valor proteico en cultivo celular. |
| CA3202891A1 (en) | 2021-01-28 | 2022-08-04 | Kara Olson | Compositions and methods for treating cytokine release syndrome |
| PY2204506A (es) | 2021-01-28 | 2022-08-30 | Talem Therapeutics Llc | Anticuerpos antiglicoproteína de espiga y su uso terapéutico |
| CA3206253A1 (en) | 2021-02-04 | 2022-08-11 | Heung Rok Park | Anti-pd-1 antibody and use thereof |
| WO2022184659A1 (en) | 2021-03-01 | 2022-09-09 | Quadrucept Bio Limited | Antibody domains & multimers |
| TW202246325A (zh) | 2021-03-03 | 2022-12-01 | 美商再生元醫藥公司 | 用於定量及修飾蛋白質黏度之系統及方法 |
| EP4305067A1 (en) | 2021-03-09 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
| US11859012B2 (en) | 2021-03-10 | 2024-01-02 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and GPC3 |
| CN117321087A (zh) | 2021-03-26 | 2023-12-29 | 先天制药公司 | 包含与细胞因子融合用于nk细胞衔接的nkp46结合位点、癌抗原结合位点的多特异性蛋白质 |
| TW202304991A (zh) | 2021-03-29 | 2023-02-01 | 日商第一三共股份有限公司 | 穩定的多重特異性分子及其利用 |
| AR125255A1 (es) | 2021-04-02 | 2023-06-28 | Regeneron Pharma | Métodos de predicción y modulación de la glicación de una proteína |
| JP2024514530A (ja) | 2021-04-02 | 2024-04-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 切断型ｃｄｃｐ１に対する抗体およびその使用 |
| CA3214757A1 (en) | 2021-04-08 | 2022-10-13 | Andreas Loew | Multifuntional molecules binding to tcr and uses thereof |
| MX2023012724A (es) | 2021-04-27 | 2024-02-08 | Amgen Inc | Modulación de la calidad de producto de anticuerpos multiespecíficos asimétricos a través del uso de la temperatura. |
| BR112023022878A2 (pt) * | 2021-05-04 | 2024-01-23 | Regeneron Pharma | Agonistas do receptor fgf21 multiespecíficos e seus usos |
| CN117597365A (zh) | 2021-05-04 | 2024-02-23 | 再生元制药公司 | 多特异性fgf21受体激动剂及其应用 |
| KR20240007171A (ko) | 2021-05-14 | 2024-01-16 | 제넨테크, 인크. | 모수네투주맙 및 폴라투주맙 베도틴을 이용한 cd20 양성 증식성 장애의 치료 방법 |
| AU2022281461A1 (en) | 2021-05-25 | 2024-01-04 | Edelweiss Immune Inc | C-x-c motif chemokine receptor 6 (cxcr6) binding molecules, and methods of using the same |
| AU2022286340A1 (en) | 2021-06-01 | 2024-01-04 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| KR20240019786A (ko) | 2021-06-09 | 2024-02-14 | 이나뜨 파르마 에스.에이. | Cd20, nkp46, cd16에 결합하고 il-2에 접합된 다중특이적 항체 |
| WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| CN117616050A (zh) | 2021-06-09 | 2024-02-27 | 先天制药公司 | 与nkp46、细胞因子受体、肿瘤抗原和cd16a结合的多特异性蛋白质 |
| CA3218481A1 (en) | 2021-06-14 | 2022-12-22 | argenx BV | Anti-il-9 antibodies and methods of use thereof |
| US12448451B2 (en) | 2021-06-25 | 2025-10-21 | Chugai Seiyaku Kabushiki Kaisha | Anti-CTLA-4 antibody and use thereof |
| AU2022314734A1 (en) | 2021-07-19 | 2024-02-08 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
| TW202322850A (zh) * | 2021-08-05 | 2023-06-16 | 美商美國禮來大藥廠 | 抗體最佳化 |
| CA3229369A1 (en) | 2021-08-16 | 2023-02-23 | Regeneron Pharmaceuticals, Inc. | Novel il27 receptor agonists and methods of use thereof |
| US20240360233A1 (en) | 2021-08-27 | 2024-10-31 | Board Of Regents, The University Of Texas System | Anti-tslpr (crlf2) antibodies |
| AR127743A1 (es) | 2021-09-06 | 2024-02-28 | Genmab Bv | Anticuerpos capaces de unirse a cd27, variantes y usos de los mismos |
| AR127006A1 (es) | 2021-09-08 | 2023-12-06 | Regeneron Pharma | UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc |
| US20250017183A1 (en) | 2021-11-04 | 2025-01-16 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a modified cacng1 locus |
| US12559576B2 (en) | 2021-11-11 | 2026-02-24 | Regeneron Pharmaceuticals, Inc. | CD20-PD1 binding molecules and methods of use thereof |
| MX2024006187A (es) | 2021-11-24 | 2024-08-14 | Regeneron Pharma | Métodos para tratar el cáncer con anticuerpos biespecíficos anti-cd3 x muc16 y anticuerpos anti-ctla-4. |
| WO2023100829A1 (ja) | 2021-11-30 | 2023-06-08 | 第一三共株式会社 | プロテアーゼ分解性マスク抗体 |
| WO2023107957A1 (en) | 2021-12-06 | 2023-06-15 | Regeneron Pharmaceuticals, Inc. | Antagonist anti-npr1 antibodies and methods of use thereof |
| AU2022408167A1 (en) | 2021-12-08 | 2024-06-06 | Regeneron Pharmaceuticals, Inc. | Mutant myocilin disease model and uses thereof |
| EP4451863A1 (en) | 2021-12-20 | 2024-10-30 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising humanized ace2 and tmprss loci |
| MX2024008055A (es) | 2022-01-07 | 2024-09-06 | Regeneron Pharma | Métodos para tratar el cáncer ovarico recurrente con anticuerpos biespecificos anti-muc16 x anti-cd3 solos o en combinación con anticuerpos anti-pd-1. |
| TW202337900A (zh) | 2022-01-12 | 2023-10-01 | 美商再生元醫藥公司 | 改良使用親和層析的異二聚蛋白質自雜質之解析的方法 |
| US20250084169A1 (en) | 2022-01-12 | 2025-03-13 | Biomolecular Holdings Llc | Nk/monocyte engagers |
| WO2023150798A1 (en) | 2022-02-07 | 2023-08-10 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for defining optimal treatment timeframes in lysosomal disease |
| AU2023218678A1 (en) | 2022-02-09 | 2024-08-01 | Daiichi Sankyo Company, Limited | Environmentally responsive masked antibody and use thereof |
| CN118613498A (zh) | 2022-02-11 | 2024-09-06 | 瑞泽恩制药公司 | 用于筛选4R Tau靶向剂的组合物和方法 |
| AU2023226512A1 (en) | 2022-02-23 | 2024-08-29 | Bright Peak Therapeutics Ag | Immune antigen specific il-18 immunocytokines and uses thereof |
| IL314993A (en) * | 2022-02-23 | 2024-10-01 | Xencor Inc | Anti-cd28 x anti-psma antibodies |
| US20230340128A1 (en) | 2022-02-24 | 2023-10-26 | Xencor, Inc. | Anti-cd28 x anti-msln antibodies |
| EP4482865A1 (en) | 2022-02-24 | 2025-01-01 | Xencor, Inc. | Anti-cd28 x anti-trop2 antibodies |
| TW202400228A (zh) | 2022-02-25 | 2024-01-01 | 美商再生元醫藥公司 | 減輕細胞激素釋放症候群的給藥方案 |
| WO2023176881A1 (ja) | 2022-03-16 | 2023-09-21 | 第一三共株式会社 | 多重特異的分子と免疫チェックポイント阻害剤の組み合わせ |
| IL315405A (en) | 2022-03-17 | 2024-11-01 | Regeneron Pharma | Methods for treating recurrent epithelioid sarcoma using bispecific anti-MUC16 and anti-CD3 antibodies alone or in combination with anti-PD-1 antibodies |
| WO2023196903A1 (en) | 2022-04-06 | 2023-10-12 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof |
| AU2023254191A1 (en) | 2022-04-11 | 2024-10-17 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| WO2023212677A2 (en) | 2022-04-29 | 2023-11-02 | Regeneron Pharmaceuticals, Inc. | Identification of tissue-specific extragenic safe harbors for gene therapy approaches |
| AU2023269134A1 (en) | 2022-05-09 | 2024-12-12 | Regeneron Pharmaceuticals, Inc. | Vectors and methods for in vivo antibody production |
| IL316892A (en) | 2022-05-11 | 2025-01-01 | Regeneron Pharma | Multispecific proprotein binding molecules and their uses |
| CA3253038A1 (en) | 2022-05-12 | 2023-11-16 | Genmab A/S | LIAISON AGENTS CAPABLE OF BINDING TO CD27 IN POLYTHERAPY |
| TW202409090A (zh) | 2022-05-12 | 2024-03-01 | 丹麥商珍美寶股份有限公司 | 在組合療法中能夠結合到ｃｄ２７之結合劑 |
| WO2023224912A1 (en) | 2022-05-16 | 2023-11-23 | Regeneron Pharmaceuticals, Inc. | Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies |
| CA3252182A1 (en) | 2022-05-18 | 2023-11-23 | Regeneron Pharmaceuticals, Inc. | MULTISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND TO CD38 AND 4-1BB AND ASSOCIATED USES |
| JP2025519158A (ja) | 2022-05-27 | 2025-06-24 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | インターロイキン－２プロタンパク質及びその使用 |
| CN119654338A (zh) | 2022-06-04 | 2025-03-18 | 再生元制药公司 | 白细胞介素-2蛋白质原及其用途 |
| WO2023240109A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Multispecific molecules for modulating t-cell activity, and uses thereof |
| WO2024020199A1 (en) | 2022-07-21 | 2024-01-25 | Regeneron Pharmaceuticals, Inc. | Native microfluidic ce-ms analysis of antibody charge heterogeneity |
| IL318627A (en) | 2022-07-29 | 2025-03-01 | Regeneron Pharma | Anti-TFR charge fusions and methods of using them |
| CN120112164A (zh) | 2022-07-29 | 2025-06-06 | 瑞泽恩制药公司 | 包含修饰的转铁蛋白受体基因座的非人动物 |
| CN120659627A (zh) | 2022-07-29 | 2025-09-16 | 瑞泽恩制药公司 | 用于转铁蛋白受体（tfr）介导的脑和肌肉递送的组合物和方法 |
| US20240043560A1 (en) | 2022-08-02 | 2024-02-08 | Regeneron Pharmaceuticals, Inc. | Methods of Treating Metastatic Castration-Resistant Prostate Cancer with Bispecific Anti-PSMA x Anti-CD28 Antibodies in Combination with Anti-PD-1 Antibodies |
| US20240067691A1 (en) | 2022-08-18 | 2024-02-29 | Regeneron Pharmaceuticals, Inc. | Interferon receptor agonists and uses thereof |
| KR20250048583A (ko) | 2022-08-18 | 2025-04-09 | 리제너론 파아마슈티컬스, 인크. | 인터페론 전구단백질 및 이의 용도 |
| EP4587122A1 (en) | 2022-09-15 | 2025-07-23 | Avidicure IP B.V. | Multispecific antigen binding proteins for stimulating nk cells and use thereof |
| EP4593590A1 (en) | 2022-09-29 | 2025-08-06 | Regeneron Pharmaceuticals, Inc. | Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes |
| IL319818A (en) | 2022-10-10 | 2025-05-01 | Regeneron Pharma | Methods for reducing alloantibody levels in patients requiring solid organ transplantation |
| AU2023364731A1 (en) | 2022-10-21 | 2025-04-03 | Diagonal Therapeutics Inc. | Heteromeric agonistic antibodies to il-18 receptor |
| US12030945B2 (en) | 2022-10-25 | 2024-07-09 | Seismic Therapeutic, Inc. | Variant IgG Fc polypeptides and uses thereof |
| WO2024092133A1 (en) | 2022-10-27 | 2024-05-02 | Regeneron Pharmaceuticals, Inc. | Anti-acvr1 antibodies and their use in the treatment of trauma-induced heterotopic ossification |
| US20250382378A1 (en) | 2022-10-31 | 2025-12-18 | Genmab A/S | Cd38 antibodies and uses thereof |
| AU2023371614A1 (en) | 2022-11-04 | 2025-05-15 | Regeneron Pharmaceuticals, Inc. | Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle |
| WO2024102948A1 (en) | 2022-11-11 | 2024-05-16 | Celgene Corporation | Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods |
| AU2023379457A1 (en) | 2022-11-14 | 2025-05-15 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes |
| CN120456916A (zh) | 2022-11-14 | 2025-08-08 | 瑞泽恩制药公司 | 抗fgfr3抗体和抗原结合片段及其使用方法 |
| WO2024123698A1 (en) | 2022-12-08 | 2024-06-13 | Regeneron Pharmaceuticals, Inc. | Methods to characterizing a fragment crystallizable domain of a bispecific antibody |
| JP2026500017A (ja) | 2022-12-16 | 2026-01-05 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ａａｖ粒子に結合する抗原結合分子及びその使用 |
| US12195546B2 (en) | 2022-12-19 | 2025-01-14 | Sanofi | CD28/OX40 bispecific antibodies |
| EP4638729A1 (en) | 2022-12-23 | 2025-10-29 | Regeneron Pharmaceuticals, Inc. | Ace2 fusion proteins and uses thereof |
| CN121002062A (zh) | 2023-01-13 | 2025-11-21 | 再生元制药公司 | Fgfr3结合分子及其使用方法 |
| AU2024207005A1 (en) | 2023-01-13 | 2025-08-28 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
| CN121002059A (zh) | 2023-01-20 | 2025-11-21 | 因外泰克斯公司 | 用于伴侣动物的双特异性结合剂 |
| WO2024173248A1 (en) | 2023-02-13 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | Treatment of muscle related disorders with anti-human cacng1 antibodies |
| AU2024223918A1 (en) | 2023-02-17 | 2025-09-11 | Regeneron Pharmaceuticals, Inc. | Induced nk cells responsive to cd3/taa bispecific antibodies |
| IL322890A (en) | 2023-02-28 | 2025-10-01 | Regeneron Pharma | Multispecific molecules containing an MHC-peptide complex containing an MHC domain and an antigenic peptide and a partially targeted immune cell antigen |
| CN121057744A (zh) | 2023-02-28 | 2025-12-02 | 再生元制药公司 | 多价抗刺突蛋白结合分子及其用途 |
| US20250043001A1 (en) | 2023-03-14 | 2025-02-06 | Xencor, Inc. | Anti-cd28 compositions |
| WO2024194686A2 (en) | 2023-03-17 | 2024-09-26 | Oxitope Pharma B.V. | Anti-phosphocholine antibodies and methods of use thereof |
| WO2024194685A2 (en) | 2023-03-17 | 2024-09-26 | Oxitope Pharma B.V. | Anti-phosphocholine antibodies and methods of use thereof |
| AU2024238898A1 (en) | 2023-03-22 | 2025-10-16 | Salubris Biotherapeutics, Inc. | Anti-5t4 antigen binding domains, antibody-drug conjugates and methods of use thereof |
| CN121057752A (zh) | 2023-04-07 | 2025-12-02 | 达科纳治疗有限公司 | 铰链经修饰的双特异性抗体 |
| US20250002588A1 (en) | 2023-04-07 | 2025-01-02 | Diagonal Therapeutics Inc. | Bispecific agonistic antibodies to activin a receptor like type 1 (alk1) |
| AU2024255999A1 (en) | 2023-04-14 | 2025-10-16 | Xencor, Inc. | Anti-cd28 x anti-trop2 antibodies |
| IL323870A (en) | 2023-04-14 | 2025-12-01 | Xencor Inc | Antibodies against x cd28 and anti enpp3 |
| JP2026514305A (ja) | 2023-05-01 | 2026-05-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | フェノールまたはベンジルアルコールを使用した複数回投与抗体医薬品 |
| CN121039163A (zh) | 2023-05-02 | 2025-11-28 | 瑞泽恩制药公司 | 抗人m-钙粘蛋白（cdh15）抗体、缀合物及其用于将遗传有效负载递送至肌肉细胞的用途 |
| WO2024233926A1 (en) | 2023-05-10 | 2024-11-14 | Regeneron Pharmaceuticals, Inc. | Cd20-pd1 binding molecules and methods of use thereof |
| KR20260026098A (ko) | 2023-05-12 | 2026-02-25 | 리제너론 파아마슈티컬스, 인크. | 인터페론 수용체 길항제 및 이의 용도 |
| IL324457A (en) | 2023-05-12 | 2026-01-01 | Genmab As | Antibodies capable of binding to ox40, their variants and uses thereof |
| WO2024243048A1 (en) | 2023-05-19 | 2024-11-28 | Diagonal Therapeutics Inc. | Bispecific agonistic antibodies to il12 receptor |
| IL324966A (en) | 2023-06-08 | 2026-01-01 | Regeneron Pharma | An animal model with rapid onset of Alzheimer's beta-amyloid plaque pathology |
| WO2024251884A1 (en) | 2023-06-09 | 2024-12-12 | Innate Pharma | Nk cell engager proteins comprising anti-cd20 and ant-nkp46 antibody, linked to il-2 in treatment of r/r b-nhl |
| CN121646605A (zh) | 2023-06-11 | 2026-03-10 | 再生元制药公司 | 环化抗体分子 |
| CN121399157A (zh) | 2023-06-12 | 2026-01-23 | 美国安进公司 | 淋巴毒素β受体激动剂结合蛋白 |
| EP4727973A1 (en) | 2023-06-16 | 2026-04-22 | Regeneron Pharmaceuticals, Inc. | Cd40 x cd40 bispecific antigen-binding molecules and uses thereof |
| CN121729432A (zh) | 2023-06-23 | 2026-03-24 | 派克西斯肿瘤学公司 | 抗klrg1抗体及其用途 |
| IL325400A (en) | 2023-07-10 | 2026-02-01 | Regeneron Pharma | Anti-human CACNG1 antibody-drug conjugates and their uses |
| JP2026524012A (ja) | 2023-07-10 | 2026-07-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 二重特異性ｐｄ－ｌ１×４－１ｂｂ抗体およびそれらの使用方法 |
| JP2026524011A (ja) | 2023-07-10 | 2026-07-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 二重特異性ｐｄ－ｌ１×ｃｄ２８抗体およびそれらの使用方法 |
| KR20260042526A (ko) | 2023-07-19 | 2026-03-31 | 리제너론 파아마슈티컬스, 인크. | 항-인자 XII/XIIa 항체 및 이의 용도 |
| IL326018A (en) | 2023-07-28 | 2026-03-01 | Regeneron Pharma | Introduction of anti-TFR:GAA and anti-CD63:GAA for the treatment of Pompe disease |
| AR133384A1 (es) | 2023-07-28 | 2025-09-24 | Regeneron Pharma | Anti-tfr:esfingomielinasa ácida para el tratamiento de la deficiencia de esfingomielinasa ácida |
| WO2025030044A1 (en) | 2023-08-02 | 2025-02-06 | Regeneron Pharmaceuticals, Inc. | Methods of treating clear cell renal cell carcinoma with bispecific anti-psma x anti-cd28 antibodies |
| KR20260046131A (ko) | 2023-08-02 | 2026-04-06 | 리제너론 파아마슈티컬스, 인크. | 이중특이적 항-PSMA x 항-CD28 항체를 이용한 전이성 거세-저항성 전립선암의 치료 방법 |
| US20250188166A1 (en) | 2023-08-23 | 2025-06-12 | Bright Peak Therapeutics Ag | Il-18 polypeptides fused to immune cell antigen specific binding polypeptides and uses thereof |
| EP4771050A1 (en) | 2023-08-28 | 2026-07-08 | Regeneron Pharmaceuticals, Inc. | Anti-cxcr4 antibodies and uses thereof |
| KR20260081298A (ko) | 2023-08-28 | 2026-06-02 | 젠코어 인코포레이티드 | 항-cd20 x 항-cd28 조합 요법 |
| IL327756A (en) | 2023-10-23 | 2026-06-01 | Diagonal Therapeutics Inc | Heteromeric agonistic antibodies to il-18 receptor |
| WO2025090973A2 (en) | 2023-10-27 | 2025-05-01 | Xencor, Inc. | Anti-trop2 x anti-pdl1 x anti-cd28 antibodies |
| KR20260113057A (ko) | 2023-11-14 | 2026-07-21 | 리제너론 파아마슈티컬스, 인크. | 조작된 중쇄 가변 도메인 및 이의 용도 |
| WO2025111473A1 (en) | 2023-11-21 | 2025-05-30 | Regeneron Pharmaceuticals, Inc. | Covalently surface modified adeno-associated virus production by in vitro conjugation, and purification of covalently surface modified adeno-associated virus |
| TW202539732A (zh) | 2023-11-29 | 2025-10-16 | 美商再生元醫藥公司 | 以雙特異性抗muc16×抗cd28抗體與抗pd-1抗體之組合或與雙特異性抗muc16×抗cd3抗體之組合治療復發性卵巢癌及子宮內膜癌之方法 |
| CN122249464A (zh) | 2023-11-30 | 2026-06-19 | 金麦安博股份有限公司 | 在组合疗法中的能够结合ox40的抗体 |
| WO2025122614A1 (en) | 2023-12-05 | 2025-06-12 | Regeneron Pharmaceuticals, Inc. | Il18 receptor agonists and methods of use thereof |
| GB202318820D0 (en) | 2023-12-08 | 2024-01-24 | UCB Biopharma SRL | Antibodies |
| TW202542187A (zh) | 2023-12-12 | 2025-11-01 | 美商再生元醫藥公司 | 以雙特異性抗muc16x抗cd3抗體單獨或與抗pd-1抗體組合治療子宮內膜癌之方法 |
| AU2024400671A1 (en) | 2023-12-15 | 2026-07-16 | Kyowa Kirin Co., Ltd. | Divalent bet decomposition agent and targeting molecule-drug complex |
| AU2024403128A1 (en) | 2023-12-19 | 2026-06-25 | Vectory Therapeutics B.V. | Anti-tdp-43 antibodies and uses thereof |
| WO2025151806A1 (en) | 2024-01-11 | 2025-07-17 | Regeneron Pharmaceuticals, Inc. | P75 neurotrophin receptor (p75ntr)-binding proteins and p75ntr-mediated delivery to the nervous system |
| WO2025149633A1 (en) | 2024-01-12 | 2025-07-17 | Laigo Bio B.V. | Bispecific antigen binding proteins |
| US20250242056A1 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing |
| WO2025160340A2 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2025171124A1 (en) | 2024-02-07 | 2025-08-14 | Regeneron Pharmaceuticals, Inc. | Methods of treating prostate cancer with bispecific anti-psma x anti-cd3 antibodies and bispecific anti-psma x anti-cd28 antibodies |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| US20250277048A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2025191136A1 (en) | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof |
| WO2025191139A1 (en) | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Conjugates of her2-specific antigen binding proteins and cytokines |
| WO2025191133A1 (en) | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Il-21 muteins, fusion proteins comprising the same and uses thereof |
| WO2025199278A2 (en) | 2024-03-20 | 2025-09-25 | Regeneron Pharmaceuticals, Inc. | Masked multispecific antigen-binding molecules with cleavable linkers |
| WO2025199243A1 (en) | 2024-03-20 | 2025-09-25 | Regeneron Pharmaceuticals, Inc. | Trivalent multispecific binding molecules and methods of use thereof |
| WO2025213061A2 (en) | 2024-04-04 | 2025-10-09 | Ethyreal Bio, Inc. | Anti-tshr antibodies and uses thereof |
| WO2025221728A2 (en) | 2024-04-15 | 2025-10-23 | Janssen Biotech, Inc. | Ltbr binding molecules and uses thereof |
| TW202611075A (zh) | 2024-05-13 | 2026-03-16 | 美商再生元醫藥公司 | 以雙特異性BCMAxCD3抗體治療輕鏈類澱粉變性症之方法 |
| WO2025240335A1 (en) | 2024-05-13 | 2025-11-20 | Regeneron Pharmaceuticals, Inc. | Fgfr3 binding molecules and methods of use thereof |
| WO2025244973A1 (en) | 2024-05-20 | 2025-11-27 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bispecific bcma x cd3 antibodies |
| US20250361309A1 (en) | 2024-05-24 | 2025-11-27 | Regeneron Pharmaceuticals, Inc. | Tumor-targeted split il12 receptor agonists |
| WO2025250495A1 (en) | 2024-05-28 | 2025-12-04 | Regeneron Pharmaceuticals, Inc. | Acceleration of human hepatocyte engraftment in humanized liver animals by supplementing paracrine ligands or agonists that activate human liver regeneration signals |
| WO2025255452A2 (en) | 2024-06-07 | 2025-12-11 | Regeneron Pharmaceuticals, Inc. | Antigen-binding molecules that bind to aav particles and uses thereof |
| WO2025255480A1 (en) | 2024-06-07 | 2025-12-11 | Regeneron Pharmaceuticals, Inc. | Tetravalent multispecific binding molecules and methods of use thereof |
| US20260055171A1 (en) | 2024-06-11 | 2026-02-26 | Regeneron Pharmaceuticals, Inc. | Vegf antagonists and methods of use thereof |
| US20260000758A1 (en) | 2024-06-28 | 2026-01-01 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen binding molecules that bind gdf8 and activin a and uses thereof |
| WO2026011013A1 (en) | 2024-07-02 | 2026-01-08 | Epibiologics, Inc. | Binding agents and uses thereof |
| TW202617776A (zh) | 2024-07-10 | 2026-05-01 | 美商再生元醫藥公司 | 治療ｓｍａｒｃｂ１缺陷型癌症之方法 |
| US20260014252A1 (en) | 2024-07-11 | 2026-01-15 | Regeneron Pharmaceuticals, Inc. | GPRC5D x CD28 Bispecific Antibodies and Methods of Use Thereof |
| WO2026025058A1 (en) | 2024-07-25 | 2026-01-29 | Regeneron Pharmaceuticals, Inc. | Aav viral particles retargeted to egfr-expressing cancer cells |
| WO2026039325A2 (en) | 2024-08-12 | 2026-02-19 | Regeneron Pharmaceuticals, Inc. | Modified mtm1 genes and uses thereof |
| WO2026039791A1 (en) | 2024-08-16 | 2026-02-19 | Regeneron Pharmaceuticals, Inc. | Tumor-targeted split il2 receptor agonists |
| WO2026044000A1 (en) | 2024-08-20 | 2026-02-26 | Ethyreal Bio, Inc. | Multispecific antibodies and methods of use thereof |
| WO2026050255A2 (en) | 2024-08-27 | 2026-03-05 | Regeneron Pharmaceuticals, Inc. | Anti-slc3a2-apis antigen-binding proteins and methods of use thereof |
| WO2026050572A2 (en) | 2024-08-29 | 2026-03-05 | Marengo Therapeutics, Inc. | Multifunctional molecules binding to tcr and uses thereof |
| WO2026055669A2 (en) | 2024-09-09 | 2026-03-12 | Xencor, Inc. | Anti-tl1a x anti-il23 antibodies |
| WO2026059917A1 (en) | 2024-09-10 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bcma inhibitors in combination with proteasome inhibitors |
| WO2026059920A1 (en) | 2024-09-10 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bcma inhibitors in combination with pd1/pd-l1 inhibitors |
| US20260070998A1 (en) | 2024-09-10 | 2026-03-12 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bcma inhibitors in combination with cd38 inhibitors |
| WO2026059923A1 (en) | 2024-09-10 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bcma inhibitors in combination with an immunomodulator |
| US20260158137A1 (en) | 2024-09-10 | 2026-06-11 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bcma inhibitors in combination with lag3 inhibitors |
| WO2026075989A1 (en) | 2024-10-01 | 2026-04-09 | Regeneron Pharmaceuticals, Inc. | Engineered igg molecules and methods of use thereof |
| WO2026076013A1 (en) | 2024-10-01 | 2026-04-09 | Regeneron Pharmaceuticals, Inc. | Tumor-targeted il2 receptor agonists and multispecific t-cell engagers |
| WO2026075981A1 (en) | 2024-10-01 | 2026-04-09 | Regeneron Pharmaceuticals, Inc. | Methods of analyzing heterodimeric proteins |
| US20260234273A1 (en) | 2024-10-09 | 2026-08-13 | Diagonal Therapeutics Inc. | Bone morphogenetic protein receptor type 2 (bmprii) antibodies |
| WO2026080752A2 (en) | 2024-10-09 | 2026-04-16 | Diagonal Therapeutics Inc. | De novo antibodies to activin a receptor like type 1 (alk1) |
| WO2026080757A2 (en) | 2024-10-09 | 2026-04-16 | Diagonal Therapeutics Inc. | Activin receptor type ii a/b (actriia/b) antibodies |
| WO2026078231A1 (en) | 2024-10-11 | 2026-04-16 | T-Therapeutics Limited | Soluble non-aggregating immune ligand |
| WO2026083296A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains |
| WO2026083295A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains |
| US20260113004A1 (en) | 2024-10-21 | 2026-04-23 | Rgb Systems, Inc. | Class d amplifier with current mode control |
| US20260109746A1 (en) | 2024-10-22 | 2026-04-23 | Gilead Sciences, Inc. | Cd4-targeted il-15 molecules and methods of use |
| WO2026087747A1 (en) | 2024-10-24 | 2026-04-30 | Avidicure Ip B.V. | Multispecific antigen binding proteins for tumor-targeting of γδ1 t cells and use thereof |
| WO2026087748A1 (en) | 2024-10-24 | 2026-04-30 | Avidicure Ip B.V. | Multispecific antigen binding proteins for the expansion of γδ t cells and use thereof |
| US20260146100A1 (en) | 2024-10-30 | 2026-05-28 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules that bind cd22 and 4-1bb and methods of use thereof |
| WO2026096576A1 (en) | 2024-10-30 | 2026-05-07 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules that bind psma and 4-1bb and methods of use thereof |
| WO2026093563A2 (en) | 2024-10-31 | 2026-05-07 | Molecular Partners Ag | Multispecific binding proteins and their use |
| WO2026102148A1 (en) | 2024-11-07 | 2026-05-15 | Diagonal Therapeutics Inc. | Alk1 / bmprii bispecific antibodies for treatment of ocular diseases |
| WO2026102284A1 (en) | 2024-11-08 | 2026-05-15 | Regeneron Pharmaceuticals, Inc. | Humanized stathmin2 allele to track human tdp-43-dependent splicing changes caused by tdp-43 pathology |
| WO2026112457A2 (en) | 2024-11-21 | 2026-05-28 | Regeneron Pharmaceuticals, Inc. | Heterodimeric antigen-binding molecules that bind to viral particles and uses thereof |
| WO2026136279A1 (en) | 2024-12-16 | 2026-06-25 | Regeneron Pharmaceuticals, Inc. | Engineered single domain antibody constructs and methods of use thereof |
| WO2026139739A1 (en) | 2024-12-27 | 2026-07-02 | Bright Peak Therapeutics Ag | Dual binding compositions targeting vegfa and pd-1 |
| WO2026161391A2 (en) | 2025-01-21 | 2026-07-30 | Bristol-Myers Squibb Company | Cd19 binding molecules including cd3- and cd19- bispecific t cell engagers and related methods and uses |
| WO2026161387A1 (en) | 2025-01-21 | 2026-07-30 | Bristol-Myers Squibb Company | Cd3 binding molecules and related methods and uses |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444878A (en) * | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
| WO1986002068A1 (fr) | 1984-09-26 | 1986-04-10 | Takeda Chemical Industries, Ltd. | Separation mutuelle de proteines |
| JPH09100296A (ja) * | 1984-09-26 | 1997-04-15 | Takeda Chem Ind Ltd | 蛋白質の相互分離方法 |
| GB8626413D0 (en) | 1986-11-05 | 1986-12-03 | Gilliland L K | Antibodies |
| GB8626412D0 (en) | 1986-11-05 | 1986-12-03 | Clark M R | Antibodies |
| AU4116793A (en) * | 1992-04-24 | 1993-11-29 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US5456909A (en) * | 1992-08-07 | 1995-10-10 | T Cell Sciences, Inc. | Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo |
| US5945311A (en) * | 1994-06-03 | 1999-08-31 | GSF--Forschungszentrumfur Umweltund Gesundheit | Method for producing heterologous bi-specific antibodies |
| DE4419399C1 (de) * | 1994-06-03 | 1995-03-09 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von heterologen bispezifischen Antikörpern |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| JPH0987300A (ja) * | 1995-07-14 | 1997-03-31 | Takeda Chem Ind Ltd | 雑種蛋白質およびその用途 |
| DK0826695T3 (da) | 1996-09-03 | 2002-04-15 | Gsf Forschungszentrum Umwelt | Tilintetgørelse af kontaminerende tumorceller i stamcelletransplantater med bispecifikke antistoffer |
| EP0826696B1 (de) * | 1996-09-03 | 2002-05-29 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität |
| US20020062010A1 (en) * | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| DE19725586C2 (de) | 1997-06-17 | 1999-06-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper |
| ATE255420T1 (de) | 1998-09-25 | 2003-12-15 | Horst Lindhofer | Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung |
| AU2001270609A1 (en) * | 2000-06-30 | 2002-01-14 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
| US7169903B2 (en) | 2001-12-21 | 2007-01-30 | Biosynexus Incorporated | Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria |
| US20030224000A1 (en) * | 2001-12-21 | 2003-12-04 | Kokai-Kun John Fitzgerald | Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies |
| NZ537277A (en) | 2002-07-18 | 2008-04-30 | Crucell Holland Bv | Recombinant production of mixtures of antibodies |
| SI1545574T1 (sl) * | 2002-09-13 | 2014-10-30 | Biogen Idec Inc. | Postopek za čiščenje polipeptidov s simulirano "moving bed" kromatografijo |
| US20090010920A1 (en) * | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| WO2005021594A2 (en) * | 2003-08-29 | 2005-03-10 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Minimally immunogenic variants of sdr-grafted humanized antibody cc49 and their use |
| US7923538B2 (en) | 2005-07-22 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd | Recombinant antibody composition |
| NZ569988A (en) * | 2006-02-01 | 2011-09-30 | Cephalon Australia Pty Ltd | Domain antibody construct which binds to human TNF-alpha and contains a modified hinge region sequence and a truncated CH1 domain |
| JP5144499B2 (ja) * | 2006-03-31 | 2013-02-13 | 中外製薬株式会社 | 二重特異性抗体を精製するための抗体改変方法 |
| CA2669412A1 (en) * | 2007-01-23 | 2008-07-31 | Xencor, Inc. | Optimized cd40 antibodies and methods of using the same |
| WO2008152537A2 (en) * | 2007-06-14 | 2008-12-18 | Zenotech Laboratories Limited | Humanized monoclonal antibodies against human epidermal growth factor receptor, use and method thereof |
| US9266967B2 (en) * | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| JO3672B1 (ar) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| TWI507525B (zh) | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| CA2791109C (en) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
-
2010
- 2010-06-25 TW TW099120735A patent/TWI507525B/zh active
- 2010-06-25 ES ES15181155T patent/ES2865648T3/es active Active
- 2010-06-25 CN CN201410072042.6A patent/CN103833855A/zh active Pending
- 2010-06-25 EP EP10726775A patent/EP2445936A1/en not_active Ceased
- 2010-06-25 EP EP15181155.1A patent/EP2975051B1/en active Active
- 2010-06-25 KR KR1020127001344A patent/KR20120027055A/ko not_active Ceased
- 2010-06-25 CA CA2766220A patent/CA2766220C/en active Active
- 2010-06-25 KR KR1020167033847A patent/KR101835648B1/ko active Active
- 2010-06-25 SG SG2011092970A patent/SG176868A1/en unknown
- 2010-06-25 MY MYPI2022004149A patent/MY199658A/en unknown
- 2010-06-25 US US12/823,838 patent/US8586713B2/en active Active
- 2010-06-25 RU RU2012102602/10A patent/RU2522002C2/ru active
- 2010-06-25 LT LTEP15181155.1T patent/LT2975051T/lt unknown
- 2010-06-25 AU AU2010265933A patent/AU2010265933B2/en active Active
- 2010-06-25 PL PL15181155T patent/PL2975051T3/pl unknown
- 2010-06-25 SI SI201032069T patent/SI2975051T1/sl unknown
- 2010-06-25 SM SM20210250T patent/SMT202100250T1/it unknown
- 2010-06-25 DK DK15181155.1T patent/DK2975051T3/da active
- 2010-06-25 MX MX2019012601A patent/MX384993B/es unknown
- 2010-06-25 MX MX2014000219A patent/MX342623B/es unknown
- 2010-06-25 KR KR1020187027792A patent/KR102010827B1/ko active Active
- 2010-06-25 KR KR1020147023291A patent/KR101747103B1/ko active Active
- 2010-06-25 HU HUE15181155A patent/HUE054257T2/hu unknown
- 2010-06-25 EP EP21160445.9A patent/EP3916011A1/en active Pending
- 2010-06-25 MX MX2011014008A patent/MX2011014008A/es active IP Right Grant
- 2010-06-25 MX MX2016010714A patent/MX368932B/es unknown
- 2010-06-25 MY MYPI2011006152 patent/MY152963A/en unknown
- 2010-06-25 CN CN201080032565.8A patent/CN102471378B/zh not_active Ceased
- 2010-06-25 KR KR1020187005989A patent/KR101904065B1/ko active Active
- 2010-06-25 WO PCT/US2010/040028 patent/WO2010151792A1/en not_active Ceased
- 2010-06-25 MY MYPI2017703816A patent/MY192182A/en unknown
- 2010-06-25 PT PT151811551T patent/PT2975051T/pt unknown
- 2010-06-25 JP JP2012517780A patent/JP5816170B2/ja active Active
- 2010-06-25 MY MYPI2014001118A patent/MY164121A/en unknown
-
2011
- 2011-12-15 IL IL217000A patent/IL217000A0/en active IP Right Grant
- 2011-12-16 MX MX2021009234A patent/MX2021009234A/es unknown
-
2013
- 2013-09-24 US US14/034,906 patent/US9309326B2/en active Active
-
2014
- 2014-04-10 RU RU2014114172/10A patent/RU2569157C2/ru active
-
2015
- 2015-07-31 AU AU2015207952A patent/AU2015207952B2/en active Active
- 2015-09-25 JP JP2015187704A patent/JP6247673B2/ja active Active
- 2015-09-25 RU RU2015140911A patent/RU2647758C2/ru active
-
2016
- 2016-03-01 US US15/058,026 patent/US9982013B2/en active Active
-
2017
- 2017-11-17 JP JP2017221813A patent/JP2018035193A/ja not_active Withdrawn
-
2018
- 2018-04-24 US US15/961,669 patent/US11168111B2/en active Active
-
2019
- 2019-03-31 IL IL265732A patent/IL265732B/en active IP Right Grant
-
2020
- 2020-10-15 JP JP2020173738A patent/JP7153048B2/ja active Active
-
2021
- 2021-04-22 HR HRP20210637TT patent/HRP20210637T1/hr unknown
- 2021-05-05 CY CY20211100378T patent/CY1124358T1/el unknown
- 2021-10-07 US US17/496,263 patent/US12157758B2/en active Active
-
2022
- 2022-07-19 US US17/868,305 patent/US20220389055A1/en active Pending
- 2022-09-30 JP JP2022157863A patent/JP2022173489A/ja not_active Withdrawn
-
2024
- 2024-12-11 JP JP2024216456A patent/JP2025026680A/ja active Pending
-
2026
- 2026-04-03 US US19/639,002 patent/US20260209266A1/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015227386A (ja) * | 2009-06-26 | 2015-12-17 | リジェネロン・ファーマシューティカルズ・インコーポレ | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| US11485790B2 (en) | 2014-04-07 | 2022-11-01 | Chugai Seiyaku Kabushiki Kaisha | Immunoactivating antigen-binding molecule |
| US11505605B2 (en) | 2014-05-13 | 2022-11-22 | Chugai Seiyaku Kabushiki Kaisha | T cell-redirected antigen-binding molecule for cells having immunosuppression function |
| US9975966B2 (en) | 2014-09-26 | 2018-05-22 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing theraputic agent |
| US11001643B2 (en) | 2014-09-26 | 2021-05-11 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
| US11649293B2 (en) | 2015-11-18 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for enhancing humoral immune response |
| US11660340B2 (en) | 2015-11-18 | 2023-05-30 | Chugai Seiyaku Kabushiki Kaisha | Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7153048B2 (ja) | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 | |
| HK40064507A (en) | Readily isolated bispecific antibodies with native immunoglobulin format | |
| HK1219283B (en) | Readily isolated bispecific antibodies with native immunoglobulin format |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130612 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130612 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141021 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150115 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150218 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150323 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150826 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150925 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5816170 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |